NZ623283B2 - Methods for treating vascular leak syndrome and cancer - Google Patents
Methods for treating vascular leak syndrome and cancer Download PDFInfo
- Publication number
- NZ623283B2 NZ623283B2 NZ623283A NZ62328312A NZ623283B2 NZ 623283 B2 NZ623283 B2 NZ 623283B2 NZ 623283 A NZ623283 A NZ 623283A NZ 62328312 A NZ62328312 A NZ 62328312A NZ 623283 B2 NZ623283 B2 NZ 623283B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- hptpb
- use according
- binding agent
- cancer
- ecd
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims abstract description 73
- 201000010874 syndrome Diseases 0.000 title claims abstract description 26
- 201000011510 cancer Diseases 0.000 title claims description 65
- 239000011230 binding agent Substances 0.000 claims abstract description 159
- 239000003814 drug Substances 0.000 claims abstract description 31
- 239000011780 sodium chloride Substances 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 102000004965 antibodies Human genes 0.000 claims description 132
- 108090001123 antibodies Proteins 0.000 claims description 132
- 239000000203 mixture Substances 0.000 claims description 127
- 239000003795 chemical substances by application Substances 0.000 claims description 110
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108090000623 proteins and genes Proteins 0.000 claims description 49
- 108010002350 Interleukin-2 Proteins 0.000 claims description 34
- 230000027455 binding Effects 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 29
- 102000038129 antigens Human genes 0.000 claims description 29
- 108091007172 antigens Proteins 0.000 claims description 29
- 239000007924 injection Substances 0.000 claims description 22
- 238000002347 injection Methods 0.000 claims description 19
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 19
- 230000001717 pathogenic Effects 0.000 claims description 19
- 230000035693 Fab Effects 0.000 claims description 18
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 18
- 244000052769 pathogens Species 0.000 claims description 18
- 239000000539 dimer Substances 0.000 claims description 16
- 210000004408 Hybridomas Anatomy 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- 229920002395 Aptamer Polymers 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 200000000018 inflammatory disease Diseases 0.000 claims description 8
- 206010022114 Injury Diseases 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 230000035939 shock Effects 0.000 claims description 7
- 206010025650 Malignant melanoma Diseases 0.000 claims description 6
- 208000006265 Renal Cell Carcinoma Diseases 0.000 claims description 6
- 230000002354 daily Effects 0.000 claims description 6
- 230000003211 malignant Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 239000000546 pharmaceutic aid Substances 0.000 claims description 6
- 108091008117 polyclonal antibodies Proteins 0.000 claims description 6
- 230000003442 weekly Effects 0.000 claims description 6
- 239000003443 antiviral agent Substances 0.000 claims description 5
- PQEJXGNZBLONLG-XJDOXCRVSA-N (2R)-2-amino-3-[1-[3-[2-[4-[1,3-bis(2-methoxyethylcarbamoyloxy)propan-2-yloxy]butanoylamino]ethylamino]-3-oxopropyl]-2,5-dioxopyrrolidin-3-yl]sulfanylpropanoic acid Chemical compound COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCNC(=O)CCN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O PQEJXGNZBLONLG-XJDOXCRVSA-N 0.000 claims description 4
- 206010069351 Acute lung injury Diseases 0.000 claims description 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
- 206010014967 Ependymoma Diseases 0.000 claims description 3
- 208000005017 Glioblastoma Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 201000001169 fibrillary astrocytoma Diseases 0.000 claims description 3
- 201000007286 pilocytic astrocytoma Diseases 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 201000010133 oligodendroglioma Diseases 0.000 claims description 2
- 206010002224 Anaplastic astrocytoma Diseases 0.000 claims 2
- 206010063836 Atrioventricular septal defect Diseases 0.000 claims 2
- 201000011626 grade III astrocytoma Diseases 0.000 claims 2
- 241000233866 Fungi Species 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000004027 cells Anatomy 0.000 description 66
- 101710037124 TEK Proteins 0.000 description 51
- 235000018102 proteins Nutrition 0.000 description 47
- 201000010099 disease Diseases 0.000 description 39
- -1 darpins Proteins 0.000 description 38
- 230000000694 effects Effects 0.000 description 36
- 230000002401 inhibitory effect Effects 0.000 description 34
- 102000000588 Interleukin-2 Human genes 0.000 description 33
- 206010027476 Metastasis Diseases 0.000 description 33
- 206010028980 Neoplasm Diseases 0.000 description 32
- 239000002246 antineoplastic agent Substances 0.000 description 31
- 238000000034 method Methods 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 23
- 230000001603 reducing Effects 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 21
- 238000004166 bioassay Methods 0.000 description 20
- 241000124008 Mammalia Species 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000003981 vehicle Substances 0.000 description 16
- 210000002889 Endothelial Cells Anatomy 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 102100007747 ANGPT2 Human genes 0.000 description 13
- 108010048036 Angiopoietin-2 Proteins 0.000 description 13
- 229940079593 drugs Drugs 0.000 description 13
- 239000002609 media Substances 0.000 description 13
- 239000001301 oxygen Substances 0.000 description 13
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 102100001937 PTPRB Human genes 0.000 description 12
- 101700082725 PTPRB Proteins 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 241000193738 Bacillus anthracis Species 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 201000009910 diseases by infectious agent Diseases 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 241000229754 Iva xanthiifolia Species 0.000 description 10
- 210000002966 Serum Anatomy 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000002202 Polyethylene glycol Substances 0.000 description 9
- 230000001965 increased Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000001519 tissues Anatomy 0.000 description 9
- 206010060945 Bacterial infection Diseases 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 102000018358 Immunoglobulins Human genes 0.000 description 8
- 108060003951 Immunoglobulins Proteins 0.000 description 8
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 8
- 208000001756 Virus Disease Diseases 0.000 description 8
- 230000033115 angiogenesis Effects 0.000 description 8
- 230000000973 chemotherapeutic Effects 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- KBNIFDASRCWYGC-GXNXWABVSA-J Evans blue Chemical compound [Na+].[Na+].[Na+].[Na+].C\1=CC2=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C(N)=C2C(=O)C/1=N/NC(C(C)=C1)=CC=C1C1=CC=C(N\N=C/2C(C3=C(N)C(=CC(=C3C=C\2)S([O-])(=O)=O)S([O-])(=O)=O)=O)C(C)=C1 KBNIFDASRCWYGC-GXNXWABVSA-J 0.000 description 7
- 206010038932 Retinopathy Diseases 0.000 description 7
- 206010038923 Retinopathy Diseases 0.000 description 7
- 206010047461 Viral infection Diseases 0.000 description 7
- 239000003183 carcinogenic agent Substances 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 230000000865 phosphorylative Effects 0.000 description 7
- 229920001469 poly(aryloxy)thionylphosphazene Polymers 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 210000004881 tumor cells Anatomy 0.000 description 7
- 230000017613 viral reproduction Effects 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 206010006187 Breast cancer Diseases 0.000 description 6
- 229920002676 Complementary DNA Polymers 0.000 description 6
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 6
- 210000004379 Membranes Anatomy 0.000 description 6
- 229940083542 Sodium Drugs 0.000 description 6
- 229940035295 Ting Drugs 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 201000009030 carcinoma Diseases 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000002708 enhancing Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037240 fusion proteins Human genes 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 229960001322 trypsin Drugs 0.000 description 6
- 206010003571 Astrocytoma Diseases 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 210000003038 Endothelium Anatomy 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 210000000987 Immune System Anatomy 0.000 description 5
- 102000004851 Immunoglobulin G Human genes 0.000 description 5
- 108090001095 Immunoglobulin G Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 229960001592 Paclitaxel Drugs 0.000 description 5
- 231100000765 Toxin Toxicity 0.000 description 5
- 230000001058 adult Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000000670 limiting Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated Effects 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 229960000060 monoclonal antibodies Drugs 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 230000000087 stabilizing Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229930003347 taxol Natural products 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 230000003612 virological Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101700023370 Ang3 Proteins 0.000 description 4
- 210000000988 Bone and Bones Anatomy 0.000 description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 4
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 4
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 4
- 229960003699 Evans blue Drugs 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 239000012593 Hanks’ Balanced Salt Solution Substances 0.000 description 4
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 102100011311 KNG1 Human genes 0.000 description 4
- 210000004185 Liver Anatomy 0.000 description 4
- 206010061289 Metastatic neoplasm Diseases 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 229920001850 Nucleic acid sequence Polymers 0.000 description 4
- 210000002381 Plasma Anatomy 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 102100009178 RUNX1T1 Human genes 0.000 description 4
- 101710034060 RUNX1T1 Proteins 0.000 description 4
- 210000001525 Retina Anatomy 0.000 description 4
- 102000005632 Single-Chain Antibodies Human genes 0.000 description 4
- 108010070144 Single-Chain Antibodies Proteins 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 239000004037 angiogenesis inhibitor Substances 0.000 description 4
- 230000003042 antagnostic Effects 0.000 description 4
- 230000000840 anti-viral Effects 0.000 description 4
- 239000012298 atmosphere Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229960003405 ciprofloxacin Drugs 0.000 description 4
- 230000000875 corresponding Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 230000002255 enzymatic Effects 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 230000000302 ischemic Effects 0.000 description 4
- 230000001665 lethal Effects 0.000 description 4
- 231100000518 lethal Toxicity 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 230000003000 nontoxic Effects 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920000023 polynucleotide Polymers 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 230000004083 survival Effects 0.000 description 4
- 230000001225 therapeutic Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 3
- HBOCNGZYIAZFSU-UHFFFAOYSA-N 3-(4-hydroxyphenyl)-2-(phosphonoamino)propanoic acid Chemical group OP(=O)(O)NC(C(=O)O)CC1=CC=C(O)C=C1 HBOCNGZYIAZFSU-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- 102100007742 ANGPT1 Human genes 0.000 description 3
- 108060001001 BRK1 Proteins 0.000 description 3
- 229940065181 Bacillus anthracis Drugs 0.000 description 3
- QXZGBUJJYSLZLT-FDISYFBBSA-N Bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
- 241000282836 Camelus dromedarius Species 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 210000003989 Endothelium, Vascular Anatomy 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 229960004338 Leuprorelin Drugs 0.000 description 3
- 210000004072 Lung Anatomy 0.000 description 3
- 210000001165 Lymph Nodes Anatomy 0.000 description 3
- 206010029113 Neovascularisation Diseases 0.000 description 3
- 206010030124 Oedema peripheral Diseases 0.000 description 3
- 229920000272 Oligonucleotide Polymers 0.000 description 3
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 3
- 208000007135 Retinal Neovascularization Diseases 0.000 description 3
- 101710043164 Segment-4 Proteins 0.000 description 3
- 206010040070 Septic shock Diseases 0.000 description 3
- 229940091252 Sodium supplements Drugs 0.000 description 3
- 229950006050 Spiromustine Drugs 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 229940076185 Staphylococcus aureus Drugs 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 101700038759 VP1 Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000000259 anti-tumor Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 108091006028 chimera Proteins 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 229960003901 dacarbazine Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 230000003511 endothelial Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 229960005277 gemcitabine Drugs 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 101700005460 hemA Proteins 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000001394 metastastic Effects 0.000 description 3
- 201000009251 multiple myeloma Diseases 0.000 description 3
- 230000003472 neutralizing Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000036303 septic shock Effects 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 2
- VPAWVRUHMJVRHU-VGDKGRGNSA-N (2R,4R)-N,N-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- NMUSYJAQQFHJEW-ARQDHWQXSA-N 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
- MOCVYVBNJQIVOV-TVQRCGJNSA-N 5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]-2-methylchromen-4-one Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C)=CC2=O MOCVYVBNJQIVOV-TVQRCGJNSA-N 0.000 description 2
- OVMSOCFBDVBLFW-VHLOTGQHSA-N 5β,20-epoxy-1,7β,13α-trihydroxy-9-oxotax-11-ene-2α,4α,10β-triyl 4,10-diacetate 2-benzoate Chemical compound O([C@@H]1[C@@]2(C[C@H](O)C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)O)C(=O)C1=CC=CC=C1 OVMSOCFBDVBLFW-VHLOTGQHSA-N 0.000 description 2
- 229950004955 ADOZELESIN Drugs 0.000 description 2
- 101710027066 ALB Proteins 0.000 description 2
- 101710040001 ANG Proteins 0.000 description 2
- 101710043860 ANGPT1 Proteins 0.000 description 2
- 101710034857 ATIC Proteins 0.000 description 2
- 229960004176 Aclarubicin Drugs 0.000 description 2
- BYRVKDUQDLJUBX-UHFFFAOYSA-N Adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- 229960001220 Amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 244000303258 Annona diversifolia Species 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
- 229950006844 BIZELESIN Drugs 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 Batimastat Drugs 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- CIUUIPMOFZIWIZ-UHFFFAOYSA-N Bropirimine Chemical compound NC1=NC(O)=C(Br)C(C=2C=CC=CC=2)=N1 CIUUIPMOFZIWIZ-UHFFFAOYSA-N 0.000 description 2
- 229950009494 Bropirimine Drugs 0.000 description 2
- 210000001775 Bruch Membrane Anatomy 0.000 description 2
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- 102100006435 CSF3 Human genes 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229960004117 Capecitabine Drugs 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 2
- 210000002421 Cell Wall Anatomy 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N DEOXYTHYMIDINE Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 229950004203 Droloxifene Drugs 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 229950011548 FADROZOLE Drugs 0.000 description 2
- 229950005096 FAZARABINE Drugs 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 2
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 229960002949 Fluorouracil Drugs 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 206010018092 Generalised oedema Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- 208000006572 Human Influenza Diseases 0.000 description 2
- 108010064750 Humanized Monoclonal Antibodies Proteins 0.000 description 2
- 102000015434 Humanized Monoclonal Antibodies Human genes 0.000 description 2
- 241000282619 Hylobates lar Species 0.000 description 2
- BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 229950006905 ILMOFOSINE Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 102000004854 Immunoglobulin M Human genes 0.000 description 2
- 231100000608 Immunotoxin Toxicity 0.000 description 2
- 108010004484 Immunotoxins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 2
- 206010022000 Influenza Diseases 0.000 description 2
- 101710026201 JCHAIN Proteins 0.000 description 2
- 102100007033 JCHAIN Human genes 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 206010024324 Leukaemias Diseases 0.000 description 2
- 210000000265 Leukocytes Anatomy 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025135 Lupus erythematosus Diseases 0.000 description 2
- 229950002676 MENOGARIL Drugs 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- 229960003951 Masoprocol Drugs 0.000 description 2
- 210000000138 Mast Cells Anatomy 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N Menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NJSMWLQOCQIOPE-OCHFTUDZSA-N N-[(E)-[10-[(E)-(4,5-dihydro-1H-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1H-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- 108091007229 NSP3 Papain-like protease domain Proteins 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N Oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229960005343 Ondansetron Drugs 0.000 description 2
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 229950008017 Ormaplatin Drugs 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 229950009351 Perfosfamide Drugs 0.000 description 2
- 208000005228 Pericardial Effusion Diseases 0.000 description 2
- 208000007641 Pinealoma Diseases 0.000 description 2
- 206010035228 Plasma cell neoplasms Diseases 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001451 Polypropylene glycol Polymers 0.000 description 2
- 229960004293 Porfimer Sodium Drugs 0.000 description 2
- 229950004406 Porfiromycin Drugs 0.000 description 2
- 208000005333 Pulmonary Edema Diseases 0.000 description 2
- 206010037423 Pulmonary oedema Diseases 0.000 description 2
- BBNQQADTFFCFGB-UHFFFAOYSA-N Purpurin Natural products C1=CC=C2C(=O)C3=C(O)C(O)=CC(O)=C3C(=O)C2=C1 BBNQQADTFFCFGB-UHFFFAOYSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 102100017879 S100A9 Human genes 0.000 description 2
- 229960004249 Sodium Acetate Drugs 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 108010090091 TIE-2 Receptor Proteins 0.000 description 2
- 102000012753 TIE-2 Receptor Human genes 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 102000036902 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 229950002376 Tirapazamine Drugs 0.000 description 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- 229960004824 Triptorelin Drugs 0.000 description 2
- 208000006786 Trophoblastic Neoplasm Diseases 0.000 description 2
- 210000003606 Umbilical Veins Anatomy 0.000 description 2
- 102100015249 VEGFA Human genes 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 210000003462 Veins Anatomy 0.000 description 2
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N Verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 2
- 229960003895 Verteporfin Drugs 0.000 description 2
- 210000000239 Visual Pathways Anatomy 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 2
- ODEDPKNSRBCSDO-UHFFFAOYSA-N [2-(hexadecylsulfanylmethyl)-3-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCCSCC(COC)COP([O-])(=O)OCC[N+](C)(C)C ODEDPKNSRBCSDO-UHFFFAOYSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 230000001154 acute Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 230000002491 angiogenic Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000845 anti-microbial Effects 0.000 description 2
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000003190 augmentative Effects 0.000 description 2
- 229960004574 azelastine Drugs 0.000 description 2
- 230000001580 bacterial Effects 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 229950008548 bisantrene Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 230000000271 cardiovascular Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 230000004059 degradation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent Effects 0.000 description 2
- 229950002389 diaziquone Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- WVYXNIXAMZOZFK-UHFFFAOYSA-N ethyl N-[2,5-bis(aziridin-1-yl)-4-(ethoxycarbonylamino)-3,6-dioxocyclohexa-1,4-dien-1-yl]carbamate Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 201000004933 in situ carcinoma Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 200000000003 influenza A Diseases 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 201000002529 islet cell tumor Diseases 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 230000002101 lytic Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 201000005962 mycosis fungoide Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 239000006179 pH buffering agent Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229960001744 pegaspargase Drugs 0.000 description 2
- 108010001564 pegaspargase Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 239000003881 protein kinase c inhibitor Substances 0.000 description 2
- 230000002685 pulmonary Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000000268 renotropic Effects 0.000 description 2
- 230000002207 retinal Effects 0.000 description 2
- 235000020945 retinal Nutrition 0.000 description 2
- 239000011604 retinal Substances 0.000 description 2
- 239000008299 semisolid dosage form Substances 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 239000004017 serum-free culture media Substances 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229940035044 sorbitan monolaurate Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 230000001131 transforming Effects 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 229960002730 vapreotide Drugs 0.000 description 2
- 230000004400 visual pathway Effects 0.000 description 2
- 229960001771 vorozole Drugs 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-β-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- BLOFGONIVNXZME-YDMGZANHSA-N (1R,2R,3R,4S,5R)-4-amino-5-methylsulfanylcyclopentane-1,2,3-triol Chemical compound CS[C@@H]1[C@@H](N)[C@@H](O)[C@@H](O)[C@H]1O BLOFGONIVNXZME-YDMGZANHSA-N 0.000 description 1
- YADVRLOQIWILGX-MIWLTHJTSA-N (1S,2Z,4E,8E,12E)-5,9,13-trimethyl-2-propan-2-ylcyclotetradeca-2,4,8,12-tetraen-1-ol Chemical compound CC(C)C/1=C/C=C(C)/CC\C=C(C)\CC\C=C(C)\C[C@@H]\1O YADVRLOQIWILGX-MIWLTHJTSA-N 0.000 description 1
- FXPSZLHFJDHOMI-DHZHZOJOSA-N (2E)-4-methoxy-3-methylsulfanyl-2-(nitrosomethylidene)-6-pyridin-2-yl-1H-pyridine Chemical compound COC1=C(SC)\C(=C/N=O)NC(C=2N=CC=CC=2)=C1 FXPSZLHFJDHOMI-DHZHZOJOSA-N 0.000 description 1
- LCADVYTXPLBAGB-AUQKUMLUSA-N (2E,4E,6Z,8E,10E,14E)-13-hydroxy-N-(1-hydroxypropan-2-yl)-2,10,12,14,16-pentamethyl-18-phenyloctadeca-2,4,6,8,10,14-hexaenamide Chemical compound OCC(C)NC(=O)C(\C)=C\C=C\C=C/C=C/C(/C)=C/C(C)C(O)C(\C)=C\C(C)CCC1=CC=CC=C1 LCADVYTXPLBAGB-AUQKUMLUSA-N 0.000 description 1
- NOENHWMKHNSHGX-FAZSUBJTSA-N (2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@H](CCC1)C(=O)NC(C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-FAZSUBJTSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2R)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-FNQTVZJVSA-N (2R)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1C[C@@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-FNQTVZJVSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2R)-3,4-dihydroxy-2-[(4S)-2-phenyl-1,3-dioxolan-4-yl]-2H-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- RCGXNDQKCXNWLO-YUHQQKLOSA-N (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@@H]1C)C(C)C)=C\C)C(C)C)[C@@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-YUHQQKLOSA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2R,3R,3aS,9aR)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-4-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- XDZGQQRZJDKPTG-HBNQUELISA-N (2S)-2-[(3S,6S)-6-[2-[(1R,2R,4aS,8aS)-1-hydroxy-2,4a,5,5,8a-pentamethyl-2,3,4,6,7,8-hexahydronaphthalen-1-yl]ethyl]-6-methyldioxan-3-yl]propanoic acid Chemical compound O1O[C@H]([C@H](C)C(O)=O)CC[C@@]1(C)CC[C@]1(O)[C@@]2(C)CCCC(C)(C)[C@]2(C)CC[C@H]1C XDZGQQRZJDKPTG-HBNQUELISA-N 0.000 description 1
- XVOCEQLNJQGCQG-ACRSGXKRSA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl- Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 XVOCEQLNJQGCQG-ACRSGXKRSA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N (2S)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N (2S)-2-[[4-[1-(2,4-diaminopteridin-6-yl)butan-2-yl]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2S)-2-[[4-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2S)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- YOZSEGPJAXTSFZ-ZETCQYMHSA-N (2S)-2-amino-3-(5-hydroxypyridin-2-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=N1 YOZSEGPJAXTSFZ-ZETCQYMHSA-N 0.000 description 1
- RPEPXOHTYVXVMA-CIUDSAMLSA-N (2S)-2-amino-5-[[(2S)-1-[[(1S)-1-carboxy-4-(3H-diazirin-3-yl)-4-oxobutyl]amino]-5-(3H-diazirin-3-yl)-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](CCC(=O)C1N=N1)C(O)=O)CC(=O)C1N=N1 RPEPXOHTYVXVMA-CIUDSAMLSA-N 0.000 description 1
- UUSZLLQJYRSZIS-GHRWIAHFSA-N (2S)-N-[(2R)-1-[[(3S,6R,8S,12S,13R,16R,17S,23S)-13-[(2S)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino]-4- Chemical compound CN([C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)C(CC=2C=CC(OC)=CC=2)C(=O)O[C@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-GHRWIAHFSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- LRJUYAVTHIEHAI-WRENIRACSA-N (2S,3R,5S,10R,11R,13R,14S)-17-[(2R,3R)-2,3-dihydroxy-6-methylheptan-2-yl]-2,3,5,11,14-pentahydroxy-10,13-dimethyl-1,2,3,4,9,11,12,15,16,17-decahydrocyclopenta[a]phenanthren-6-one Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)C([C@H](O)C[C@@]3(C([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@]21O LRJUYAVTHIEHAI-WRENIRACSA-N 0.000 description 1
- BEHHCQFBLOARIX-APTPAJQOSA-N (2S,3S)-2-aminooctadecane-1,3-diol;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO BEHHCQFBLOARIX-APTPAJQOSA-N 0.000 description 1
- HWMMBHOXHRVLCU-QOUANJGESA-N (2S,4S,5S)-4-[(1E,3E,5E)-7-[(2R,6R)-6-[(2R,3S,4aR,12bS)-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxo-2,4-dihydrobenzo[a]anthracen-9-yl]-2-methyloxan-3-yl]oxy-7-oxohepta-1,3,5-trienyl]-2,5-dimethyl-1,3-dioxolane-2-carboxylic acid Chemical compound C[C@@H]1O[C@](C)(C(O)=O)O[C@H]1\C=C\C=C\C=C\C(=O)OC1[C@@H](C)O[C@@H](C=2C(=C3C(=O)C4=C([C@]5(C(=O)[C@H](O)[C@@](C)(O)C[C@@]5(O)C=C4)O)C(=O)C3=CC=2)O)CC1 HWMMBHOXHRVLCU-QOUANJGESA-N 0.000 description 1
- FXPSZLHFJDHOMI-FLIBITNWSA-N (2Z)-4-methoxy-3-methylsulfanyl-2-(nitrosomethylidene)-6-pyridin-2-yl-1H-pyridine Chemical compound COC1=C(SC)\C(=C\N=O)NC(C=2N=CC=CC=2)=C1 FXPSZLHFJDHOMI-FLIBITNWSA-N 0.000 description 1
- JSUANXYBLFQZGI-HDFWGNLJSA-N (2Z,4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-5-methyl-2-(6-oxocyclohexa-2,4-dien-1-ylidene)-1,3-oxazolidine-4-carboxamide Chemical compound O=C([C@H]1NC(/O[C@@H]1C)=C\1C(C=CC=C/1)=O)N(CCCNC(=O)C=1C(=C(O)C=CC=1)O)CCCCNC(=O)C1=CC=CC(O)=C1O JSUANXYBLFQZGI-HDFWGNLJSA-N 0.000 description 1
- UYRMXZIBPZVBNO-QPJJXVBHSA-N (4E)-4-[amino-(hydroxyamino)methylidene]-2-hydroxycyclohexa-2,5-dien-1-one Chemical compound ONC(/N)=C1\C=CC(=O)C(O)=C1 UYRMXZIBPZVBNO-QPJJXVBHSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- DLWOTOMWYCRPLK-UVTDQMKNSA-N (4Z)-5-amino-6-(7-amino-6-methoxy-5,8-dioxoquinolin-2-yl)-4-(4,5-dimethoxy-6-oxocyclohexa-2,4-dien-1-ylidene)-3-methyl-1H-pyridine-2-carboxylic acid Chemical compound C1=CC(OC)=C(OC)C(=O)\C1=C\1C(N)=C(C=2N=C3C(=O)C(N)=C(OC)C(=O)C3=CC=2)NC(C(O)=O)=C/1C DLWOTOMWYCRPLK-UVTDQMKNSA-N 0.000 description 1
- GTEXXGIEZVKSLH-YPMHNXCESA-N (4aS,12bR)-8,10-dihydroxy-2,5,5,9-tetramethyl-3,4,4a,12b-tetrahydronaphtho[2,3-c]isochromene-7,12-dione Chemical compound O=C1C2=CC(O)=C(C)C(O)=C2C(=O)C2=C1[C@@H]1C=C(C)CC[C@@H]1C(C)(C)O2 GTEXXGIEZVKSLH-YPMHNXCESA-N 0.000 description 1
- HLAKJNQXUARACO-ZDUSSCGKSA-N (5'R)-5'-hydroxy-2',5',7'-trimethylspiro[cyclopropane-1,6'-indene]-4'-one Chemical compound O=C([C@@]1(O)C)C2=CC(C)=CC2=C(C)C21CC2 HLAKJNQXUARACO-ZDUSSCGKSA-N 0.000 description 1
- CPTIBDHUFVHUJK-NZYDNVMFSA-N (5R,6R,7R,8R)-N'-ethyl-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carbohydrazide Chemical compound C1([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(=O)NNCC)=CC(OC)=C(OC)C(OC)=C1 CPTIBDHUFVHUJK-NZYDNVMFSA-N 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7R,8R,9S,10R,13S,14S,17S)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- PTBPQBZWBIRISO-IAGVQPJWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(E)-N-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-C-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 PTBPQBZWBIRISO-IAGVQPJWSA-N 0.000 description 1
- KMSKQZKKOZQFFG-YXRRJAAWSA-N (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-6-methyl-5-[(2R)-oxan-2-yl]oxyoxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@@H]1CCCCO1 KMSKQZKKOZQFFG-YXRRJAAWSA-N 0.000 description 1
- RCFNNLSZHVHCEK-YGCMNLPTSA-N (7S,9S)-7-[(2S,4R,6S)-4-amino-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 RCFNNLSZHVHCEK-YGCMNLPTSA-N 0.000 description 1
- JVHPTYWUBOQMBP-RVFAQHLVSA-N (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 JVHPTYWUBOQMBP-RVFAQHLVSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- VAPSMQAHNAZRKC-PQWRYPMOSA-N (8S,9S,10R,13S,14S,17S)-17-(tert-butylcarbamoyl)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3-carboxylic acid Chemical compound C1C=C2C=C(C(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC2 VAPSMQAHNAZRKC-PQWRYPMOSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (Z,5S)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2R)-oxiran-2-yl]methyl]-3-[[(2S)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2R,3S,4R,6S)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- JQJSFAJISYZPER-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(2,3-dihydro-1H-inden-5-ylsulfonyl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NS(=O)(=O)C1=CC=C(CCC2)C2=C1 JQJSFAJISYZPER-UHFFFAOYSA-N 0.000 description 1
- NSMXQKNUPPXBRG-UHFFFAOYSA-N 1-(5-hydroxyhexyl)-3,7-dimethylpurine-2,6-dione Chemical compound O=C1N(CCCCC(O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N 2,2,2-tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- VKDGNNYJFSHYKD-UHFFFAOYSA-N 2,5-diamino-2-(difluoromethyl)pentanoic acid;hydron;chloride Chemical compound Cl.NCCCC(N)(C(F)F)C(O)=O VKDGNNYJFSHYKD-UHFFFAOYSA-N 0.000 description 1
- NJWBUDCAWGTQAS-UHFFFAOYSA-N 2-(chrysen-6-ylmethylamino)-2-methylpropane-1,3-diol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 NJWBUDCAWGTQAS-UHFFFAOYSA-N 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N 2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- JUNILAWHCDMYAE-HGJPKUQDSA-N 2-[(3E,7E,9E,17E)-14,19-dihydroxy-3,5,9,11,13,15,17-heptamethyl-12-oxononadeca-3,7,9,17-tetraenyl]-2,3-dihydropyran-6-one Chemical compound OC/C=C(C)/CC(C)C(O)C(C)C(=O)C(C)/C=C(\C)/C=C/CC(C)\C=C(/C)CCC1CC=CC(=O)O1 JUNILAWHCDMYAE-HGJPKUQDSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N 2-[[2-[bis(2-hydroxyethyl)amino]-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- CKJGHPBOPQNPHM-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;sodium Chemical compound [Na].OCCN(CCO)CCO CKJGHPBOPQNPHM-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3H-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- PCZUSAVLHNFWAD-UHFFFAOYSA-N 2-sulfanylidene-1,3,2$l^{5}-diazaphosphinan-2-amine Chemical compound NP1(=S)NCCCN1 PCZUSAVLHNFWAD-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- GTJXPMSTODOYNP-BTKVJIOYSA-N 3-[(E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 GTJXPMSTODOYNP-BTKVJIOYSA-N 0.000 description 1
- WELIVEBWRWAGOM-UHFFFAOYSA-N 3-amino-N-[2-[2-(3-aminopropanoylamino)ethyldisulfanyl]ethyl]propanamide Chemical compound NCCC(=O)NCCSSCCNC(=O)CCN WELIVEBWRWAGOM-UHFFFAOYSA-N 0.000 description 1
- XSCKKKKCZBNKQZ-UHFFFAOYSA-N 3-chloroquinoxaline-2-sulfonamide Chemical compound C1=CC=C2N=C(Cl)C(S(=O)(=O)N)=NC2=C1 XSCKKKKCZBNKQZ-UHFFFAOYSA-N 0.000 description 1
- HXZRMADPDYFMEB-MLTUFRGDSA-N 3-hydroxy-N-[3-[8-[(E)-6-hydroxy-3,5-dimethylhept-4-enyl]-3-methyl-1,7-dioxaspiro[5.5]undecan-2-yl]propyl]-2-methyl-4-[[2-[3-methyl-6-[(Z)-2-oxopent-3-enyl]oxan-2-yl]acetyl]amino]butanamide Chemical compound O1C(CC(=O)\C=C/C)CCC(C)C1CC(=O)NCC(O)C(C)C(=O)NCCCC1C(C)CCC2(OC(CCC(C)\C=C(/C)C(C)O)CCC2)O1 HXZRMADPDYFMEB-MLTUFRGDSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2H-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N 4-acetamido-N-(2-aminophenyl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- XESARGFCSKSFID-FLLFQEBCSA-N 5-[(2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1H-pyrazole-3-carboxamide Chemical compound OC1=C(C(=O)N)NN=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 XESARGFCSKSFID-FLLFQEBCSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(E)-5-[(1S)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- ZCJXQWYMBJYJNB-LRDBBFHQSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 ZCJXQWYMBJYJNB-LRDBBFHQSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N 5508-58-7 Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-Dimethoxy-Benzyl)-5-Methyl-Pyrido[2,3-D]Pyrimidine-2,4-Diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purin-2-amine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- GFYRZTLCYQQVHZ-UHFFFAOYSA-N 6-hydroxy-4-oxo-N-phenyl-2-sulfanylidene-1H-pyrimidine-5-carboxamide Chemical compound N1C(=S)NC(=O)C(C(=O)NC=2C=CC=CC=2)=C1O GFYRZTLCYQQVHZ-UHFFFAOYSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N 9-[4-(methanesulfonamido)-2-methoxyanilino]-N,5-dimethylacridine-4-carboxamide Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N ABTS Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- 229950008427 ACIVICIN Drugs 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N ACIVICIN Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 108060005293 AGA Proteins 0.000 description 1
- 102100001249 ALB Human genes 0.000 description 1
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 1
- 229940035674 ANESTHETICS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 102100004323 ASPG Human genes 0.000 description 1
- 229950004810 ATAMESTANE Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 241000566143 Accipitridae Species 0.000 description 1
- SMPZPKRDRQOOHT-UHFFFAOYSA-N Acronine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 1
- 229950000616 Acronine Drugs 0.000 description 1
- DPGOLRILOKERAV-AAWJQDODSA-N Adecypenol Chemical compound OC1C(CO)=CCC1(O)N1C(N=CNC[C@H]2O)C2N=C1 DPGOLRILOKERAV-AAWJQDODSA-N 0.000 description 1
- 208000007128 Adrenocortical Carcinoma Diseases 0.000 description 1
- 206010064930 Age-related macular degeneration Diseases 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 229950010949 Ambamustine Drugs 0.000 description 1
- 229950004821 Ambomycin Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- 229960003437 Aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N Anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-QPSYGYIJSA-N Andrographolide Natural products C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1\[C@H](O)COC1=O BOJKULTULYSRAS-QPSYGYIJSA-N 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- VGQOVCHZGQWAOI-HYUHUPJXSA-N Anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- IOASYARYEYRREA-LQAJYKIKSA-N Aphidicolin glycinate Chemical compound C1[C@]23[C@]4(C)CC[C@H](O)[C@](C)(CO)[C@H]4CC[C@@H]3C[C@@H]1[C@@](COC(=O)CN)(O)CC2 IOASYARYEYRREA-LQAJYKIKSA-N 0.000 description 1
- 206010059512 Apoptosis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 108010075389 Aspergillus restrictus MITF protein Proteins 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 229950006933 Atrimustine Drugs 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N Axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N Axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N Azasetron Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 229950005951 Azasetron Drugs 0.000 description 1
- 229950004295 Azotomycin Drugs 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 229950005567 BENZODEPA Drugs 0.000 description 1
- 229950002370 BISNAFIDE Drugs 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N Balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- 210000002469 Basement Membrane Anatomy 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N Betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- QGJZLNKBHJESQX-CASBDLHJSA-N Betulinic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2 QGJZLNKBHJESQX-CASBDLHJSA-N 0.000 description 1
- 108010005144 Bevacizumab Proteins 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 108010071919 Bispecific Antibodies Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 1
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 240000000772 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 229950002361 Budotitane Drugs 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N Buthionine sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- ZIWXKGQDQBLUMV-JUDXGUMMSA-N C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O Chemical compound C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O ZIWXKGQDQBLUMV-JUDXGUMMSA-N 0.000 description 1
- 229960005084 CALCITRIOL Drugs 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N CARUBICIN Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229950001725 CARUBICIN Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N CARZELESIN Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N CHEMBL118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- RWXRJSRJIITQAK-ZSBIGDGJSA-N CHEMBL2105109 Chemical compound C12=CC=CC=C2NC(=O)N1C(=O)N[C@H](C1)C[C@H]2CC[C@@H]1N2C RWXRJSRJIITQAK-ZSBIGDGJSA-N 0.000 description 1
- 102100016705 COL18A1 Human genes 0.000 description 1
- 229950007258 CRISNATOL Drugs 0.000 description 1
- LUEYTMPPCOCKBX-KWYHTCOPSA-N CURACIN-A Chemical compound C=CC[C@H](OC)CC\C(C)=C\C=C\CC\C=C/[C@@H]1CSC([C@H]2[C@H](C2)C)=N1 LUEYTMPPCOCKBX-KWYHTCOPSA-N 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N Calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 Calusterone Drugs 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 229950009338 Caracemide Drugs 0.000 description 1
- 229950005155 Carbetimer Drugs 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N Carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 208000002458 Carcinoid Tumor Diseases 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 229950007509 Carzelesin Drugs 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229950010667 Cedefingol Drugs 0.000 description 1
- 210000003570 Cell-Matrix Junctions Anatomy 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 229950000634 Cicaprost Drugs 0.000 description 1
- 229950011359 Cirolemycin Drugs 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- GLESHRYLRAOJPS-DHCFDGJBSA-N Conagenin Chemical compound C[C@@H](O)[C@H](C)[C@@H](O)C(=O)N[C@@](C)(CO)C(O)=O GLESHRYLRAOJPS-DHCFDGJBSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- TYVRUMCYJWCOOO-TVEJMLEISA-N Cypemycin Chemical compound C1S\C=C/NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(C(C)CC)NC(=O)C(=C\C)/NC(=O)C(CO)NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(\NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)NC(=O)C1N(CCC1)C(=O)C(\NC(=O)C(C)N(C)C)=C/C)=C/C)=C/C)C(C)C)CC1=CC=CC=C1 TYVRUMCYJWCOOO-TVEJMLEISA-N 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- 210000004292 Cytoskeleton Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010084740 Daclizumab Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229960000975 Daunorubicin Drugs 0.000 description 1
- 229960003109 Daunorubicin Hydrochloride Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- 229950005878 Dexverapamil Drugs 0.000 description 1
- 229950010621 Dezaguanine Drugs 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Didronel Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 230000036947 Dissociation constant Effects 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
- 229940115080 Doxil Drugs 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 229960002918 Doxorubicin Hydrochloride Drugs 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950005133 Duazomycin Drugs 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229950011461 EDELFOSINE Drugs 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229950010033 Ebselen Drugs 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselenum Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 229950005678 Ecomustine Drugs 0.000 description 1
- MHFRGQHAERHWKZ-UHFFFAOYSA-N Edelfosine Chemical compound CCCCCCCCCCCCCCCCCCOCC(OC)COP([O-])(=O)OCC[N+](C)(C)C MHFRGQHAERHWKZ-UHFFFAOYSA-N 0.000 description 1
- 108010070635 Edrecolomab Proteins 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N Eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- 229960002046 Eflornithine Hydrochloride Drugs 0.000 description 1
- MGQRRMONVLMKJL-KWJIQSIXSA-N Elsamitrucin Chemical compound O1[C@H](C)[C@H](O)[C@H](OC)[C@@H](N)[C@H]1O[C@@H]1[C@](O)(C)[C@@H](O)[C@@H](C)O[C@H]1OC1=CC=CC2=C(O)C(C(O3)=O)=C4C5=C3C=CC(C)=C5C(=O)OC4=C12 MGQRRMONVLMKJL-KWJIQSIXSA-N 0.000 description 1
- 229950002339 Elsamitrucin Drugs 0.000 description 1
- 229950005450 Emitefur Drugs 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 229950010625 Enloplatin Drugs 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- 229950004926 Epipropidine Drugs 0.000 description 1
- 229960003265 Epirubicin Hydrochloride Drugs 0.000 description 1
- 229950009537 Epristeride Drugs 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- 229960001766 Estramustine Phosphate Sodium Drugs 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N Etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 Etanidazole Drugs 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102100007155 FGF1 Human genes 0.000 description 1
- 101700064732 FGF1 Proteins 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 102100008658 FN1 Human genes 0.000 description 1
- 229950010404 FOSTRIECIN Drugs 0.000 description 1
- 230000036809 Fabs Effects 0.000 description 1
- 210000003754 Fetus Anatomy 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 240000001973 Ficus microcarpa Species 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229950006000 Flezelastine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 229950005682 Flurocitabine Drugs 0.000 description 1
- 229950004217 Forfenimex Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N Fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 Fosquidone Drugs 0.000 description 1
- 101710027855 GLRG_06511 Proteins 0.000 description 1
- 229950004410 Galocitabine Drugs 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 229960005144 Gemcitabine hydrochloride Drugs 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- 210000001308 Heart Ventricles Anatomy 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N Hexamethylene bisacetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 240000006600 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100014263 IGF1R Human genes 0.000 description 1
- 101700025802 IGF1R Proteins 0.000 description 1
- 229950007654 ITASETRON Drugs 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- 229960001176 Idarubicin Hydrochloride Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 229950002248 Idoxifene Drugs 0.000 description 1
- 229950009926 Idramantone Drugs 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N Ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 108090000745 Immune Sera Proteins 0.000 description 1
- 229940102223 Injectable Solution Drugs 0.000 description 1
- 229940102213 Injectable Suspension Drugs 0.000 description 1
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 1
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 229940109242 Interferon Alfa-n3 Drugs 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 229940117681 Interleukin-12 Drugs 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000008181 Intestinal Carcinoid Tumors Diseases 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N Iobenguane Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- 229950010897 Iproplatin Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229960000779 Irinotecan hydrochloride Drugs 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Iron(II) fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 229950000855 Iroplact Drugs 0.000 description 1
- 229950010984 Irsogladine Drugs 0.000 description 1
- 101700056073 KNG Proteins 0.000 description 1
- 101700036456 KNG1 Proteins 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine dizwitterion Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 229950005634 LOXORIBINE Drugs 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- POCZBHBFCIWCCV-UHFFFAOYSA-N Lamellarin N Chemical compound C1=C(O)C(OC)=CC=C1C1=C2C3=CC(OC)=C(O)C=C3C=CN2C2=C1C(C=C(OC)C(O)=C1)=C1OC2=O POCZBHBFCIWCCV-UHFFFAOYSA-N 0.000 description 1
- 201000005099 Langerhans-cell histiocytosis Diseases 0.000 description 1
- 108010062867 Lenograstim Proteins 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 1
- 229940008250 Leuprolide Drugs 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- KDQAABAKXDWYSZ-SDCRJXSCSA-N Leurosidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-SDCRJXSCSA-N 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- UGFHIPBXIWJXNA-UHFFFAOYSA-N Liarozole Chemical compound ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 UGFHIPBXIWJXNA-UHFFFAOYSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N Lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- 229950000909 Lometrexol Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N Losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 Losoxantrone Drugs 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N Losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- 210000002751 Lymph Anatomy 0.000 description 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108091007472 MAP kinase family Proteins 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N METOPRINE, METHODICHLOROPHEN Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 229950010718 MOPIDAMOL Drugs 0.000 description 1
- 102100006003 MT3 Human genes 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 210000002540 Macrophages Anatomy 0.000 description 1
- 208000002780 Macular Degeneration Diseases 0.000 description 1
- 229950001474 Maitansine Drugs 0.000 description 1
- 206010025482 Malaise Diseases 0.000 description 1
- 206010025557 Malignant fibrous histiocytoma of bone Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- 102000001544 Maspin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- 229960002868 Mechlorethamine hydrochloride Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- 229960003846 Melengestrol Acetate Drugs 0.000 description 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 1
- 208000002030 Merkel Cell Carcinoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229950008541 Mirimostim Drugs 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N Mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 Mitindomide Drugs 0.000 description 1
- 229950002137 Mitocarcin Drugs 0.000 description 1
- 102000004331 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108090000823 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 229950000911 Mitogillin Drugs 0.000 description 1
- 229960003539 Mitoguazone Drugs 0.000 description 1
- 229950007612 Mitomalcin Drugs 0.000 description 1
- 229950005715 Mitosper Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960004169 Mitoxantrone Hydrochloride Drugs 0.000 description 1
- 229950008012 Mofarotene Drugs 0.000 description 1
- VAZLWPAHMORDGR-UHFFFAOYSA-L Motexafin gadolinium Chemical compound C1=C(OCCOCCOCCOC)C(OCCOCCOCCOC)=CC2=C1[N]1=CC3=[N]4[Gd]11(N56)(OC(=O)C)(OC(=O)C)[N]2=CC(C(C)=C2CCCO)=[N]1C2=CC6=C(CC)C(CC)=C5C=C4C(CCCO)=C3C VAZLWPAHMORDGR-UHFFFAOYSA-L 0.000 description 1
- ISYPMTHOLIXZHJ-UHFFFAOYSA-N Motexafin lutetium Chemical compound [Lu].CC(O)=O.CC(O)=O.C1=NC2=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C2N=CC(C(=C2CCCO)C)=NC2=CC(C(CC)=C2CC)=NC2=CC2=C(CCCO)C(C)=C1N2 ISYPMTHOLIXZHJ-UHFFFAOYSA-N 0.000 description 1
- 206010028193 Multiple endocrine neoplasia syndrome Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 229960000951 Mycophenolic Acid Drugs 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- 206010028576 Myeloproliferative disease Diseases 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- PAVKBQLPQCDVNI-UHFFFAOYSA-N N',N'-diethyl-N-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical compound N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N,3,4-trihydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N N-[(2S,3S)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N N-[(E)-1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- ARKYUICTMUZVEW-UHFFFAOYSA-N N-[5-[[5-[(3-amino-3-iminopropyl)carbamoyl]-1-methylpyrrol-3-yl]carbamoyl]-1-methylpyrrol-3-yl]-4-[[4-[bis(2-chloroethyl)amino]benzoyl]amino]-1-methylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCC(N)=N)N(C)C=C1NC(=O)C1=CC(NC(=O)C=2N(C=C(NC(=O)C=3C=CC(=CC=3)N(CCCl)CCCl)C=2)C)=CN1C ARKYUICTMUZVEW-UHFFFAOYSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N N-[bis(aziridin-1-yl)phosphoryl]-N-ethyl-1,3,4-thiadiazol-2-amine Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- WRINSSLBPNLASA-FOCLMDBBSA-N N-methyl-N-[(E)-(N-methylanilino)diazenyl]aniline Chemical compound C=1C=CC=CC=1N(C)\N=N\N(C)C1=CC=CC=C1 WRINSSLBPNLASA-FOCLMDBBSA-N 0.000 description 1
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical compound O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- JZGDNMXSOCDEFQ-UHFFFAOYSA-N Napavin Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(O)C1(O)C(=O)NCCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O JZGDNMXSOCDEFQ-UHFFFAOYSA-N 0.000 description 1
- 229950010676 Nartograstim Drugs 0.000 description 1
- 229940097496 Nasal Spray Drugs 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 229950007221 Nedaplatin Drugs 0.000 description 1
- 229950010159 Nemorubicin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- 241001182492 Nes Species 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 description 1
- 210000001331 Nose Anatomy 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O(6)-benzylguanine; Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 229960002700 Octreotide Drugs 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- 229940041678 Oral Spray Drugs 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N Osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 Osaterone Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N Oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 Oseltamivir Drugs 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 101710027269 PECAM1 Proteins 0.000 description 1
- 229950000039 PELDESINE Drugs 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 102100012884 PF4 Human genes 0.000 description 1
- 101710014074 PF4 Proteins 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N PMSF Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 101700079089 PTPRD Proteins 0.000 description 1
- 102100005502 PTPRD Human genes 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N Palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- ZFYKZAKRJRNXGF-XRZRNGJYSA-N Palmitoyl rhizoxin Chemical compound O1C(=O)C2OC2CC(CC(=O)O2)CC2C(C)\C=C\C2OC2(C)C(OC(=O)CCCCCCCCCCCCCCC)CC1C(C)C(OC)C(\C)=C\C=C\C(\C)=C\C1=COC(C)=N1 ZFYKZAKRJRNXGF-XRZRNGJYSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- RDIMTXDFGHNINN-IKGGRYGDSA-N Panaxytriol Chemical compound CCCCCCC[C@H](O)[C@@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-IKGGRYGDSA-N 0.000 description 1
- RDIMTXDFGHNINN-BRWVUGGUSA-N Panaxytriol Natural products CCCCCCC[C@@H](O)[C@H](O)CC#CC#C[C@H](O)C=C RDIMTXDFGHNINN-BRWVUGGUSA-N 0.000 description 1
- 208000003154 Papilloma Diseases 0.000 description 1
- 229950006361 Pazelliptine Drugs 0.000 description 1
- LPHSYQSMAGVYNT-UHFFFAOYSA-N Pazelliptine Chemical compound N1C2=CC=NC=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2 LPHSYQSMAGVYNT-UHFFFAOYSA-N 0.000 description 1
- DOHVAKFYAHLCJP-UHFFFAOYSA-N Peldesine Chemical compound C1=2NC(N)=NC(=O)C=2NC=C1CC1=CC=CN=C1 DOHVAKFYAHLCJP-UHFFFAOYSA-N 0.000 description 1
- 229950006960 Peliomycin Drugs 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N Pepstatin Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 229950000964 Pepstatin Drugs 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 206010034800 Phaeochromocytoma Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 210000003800 Pharynx Anatomy 0.000 description 1
- 229960002139 Pilocarpine Hydrochloride Drugs 0.000 description 1
- QCHFTSOMWOSFHM-WPRPVWTQSA-N Pilopine HS Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229950001030 Piritrexim Drugs 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 210000004011 Plasma Cells Anatomy 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000002151 Pleural Effusion Diseases 0.000 description 1
- 229950004541 Plomestane Drugs 0.000 description 1
- JKPDEYAOCSQBSZ-OEUJLIAZSA-N Plomestane Chemical compound O=C1CC[C@]2(CC#C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKPDEYAOCSQBSZ-OEUJLIAZSA-N 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960001586 Procarbazine Hydrochloride Drugs 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- 210000002307 Prostate Anatomy 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010061471 Pseudomonas infection Diseases 0.000 description 1
- 241000739883 Pseudotetracha ion Species 0.000 description 1
- 229960004356 RIBOPRINE Drugs 0.000 description 1
- 102100020174 RYK Human genes 0.000 description 1
- 101700007713 RYK Proteins 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 229950002225 Retelliptine Drugs 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N Rhenium Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- KNUXHTWUIVMBBY-JRJYXWDASA-N Rintatolimod Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1.O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 KNUXHTWUIVMBBY-JRJYXWDASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- QXKJWHWUDVQATH-UHFFFAOYSA-N Rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 1
- 229950005230 Rogletimide Drugs 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N Roquinimex Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- 229950008902 SAFINGOL Drugs 0.000 description 1
- CGFVUVWMYIHGHS-UHFFFAOYSA-N SAINTOPIN Chemical compound C1=C(O)C=C2C=C(C(=O)C=3C(=C(O)C=C(C=3)O)C3=O)C3=C(O)C2=C1O CGFVUVWMYIHGHS-UHFFFAOYSA-N 0.000 description 1
- 108010005173 SERPIN-B5 Proteins 0.000 description 1
- 229950001403 SIZOFIRAN Drugs 0.000 description 1
- 229950007841 SULOFENUR Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229950009089 Simtrazene Drugs 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108009000491 Small cell lung cancer Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229950004225 Sonermin Drugs 0.000 description 1
- 229950004796 Sparfosic Acid Drugs 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N Sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- 229950009641 Sparsomycin Drugs 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 206010062261 Spinal cord neoplasm Diseases 0.000 description 1
- 229950004330 Spiroplatin Drugs 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229940076156 Streptococcus pyogenes Drugs 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- FXUAIOOAOAVCGD-FKSUSPILSA-N Swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- URLYINUFLXOMHP-HTVVRFAVSA-N TCN-P Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O URLYINUFLXOMHP-HTVVRFAVSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 102100002607 TIMP1 Human genes 0.000 description 1
- 102100006014 TIMP2 Human genes 0.000 description 1
- 102000033174 TMPO Human genes 0.000 description 1
- 101710026709 TMPO Proteins 0.000 description 1
- 229950002687 Talisomycin Drugs 0.000 description 1
- 229950005667 Tallimustine Drugs 0.000 description 1
- 229950010168 Tauromustine Drugs 0.000 description 1
- 229950010138 Teloxantrone Drugs 0.000 description 1
- QDZIHWBJFUNKOF-UHFFFAOYSA-N Teloxantrone Chemical compound OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC QDZIHWBJFUNKOF-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229960001278 Teniposide Drugs 0.000 description 1
- 229950008703 Teroxirone Drugs 0.000 description 1
- 208000002918 Testicular Germ Cell Tumor Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- WXZSUBHBYQYTNM-WMDJANBXSA-N Tetrazomine Chemical compound C=1([C@@H]2CO[C@@H]3[C@H]4C[C@@H](CO)[C@H](N4C)[C@@H](N23)CC=1C=C1)C(OC)=C1NC(=O)C1NCCC[C@H]1O WXZSUBHBYQYTNM-WMDJANBXSA-N 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N Thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 229940104230 Thymidine Drugs 0.000 description 1
- 208000008732 Thymoma Diseases 0.000 description 1
- 239000000898 Thymopoietin Substances 0.000 description 1
- 229950010183 Thymotrinan Drugs 0.000 description 1
- 229960002175 Thyroglobulin Drugs 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 229950011457 Tiamiprine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N Tiazofurin Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- TVPNFKRGOFJQOO-UHFFFAOYSA-N Topsentin B1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 1
- 229960004167 Toremifene Citrate Drugs 0.000 description 1
- 210000003014 Totipotent Stem Cells Anatomy 0.000 description 1
- 206010044407 Transitional cell cancer of the renal pelvis and ureter Diseases 0.000 description 1
- 229950005609 Trestolone Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229950003873 Triciribine Drugs 0.000 description 1
- 229940117013 Triethanolamine oleate Drugs 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N Turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 Turosteride Drugs 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010046766 Uterine cancer Diseases 0.000 description 1
- 108091007928 VEGF receptors Proteins 0.000 description 1
- 206010046885 Vaginal cancer Diseases 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 229950008261 Velaresol Drugs 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229960003048 Vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 1
- 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229960002110 Vincristine Sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960005212 Vindesine Sulfate Drugs 0.000 description 1
- KLFUUCHXSFIPMH-YBFGSCICSA-N Vinepidine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 KLFUUCHXSFIPMH-YBFGSCICSA-N 0.000 description 1
- 229950001270 Vinepidine Drugs 0.000 description 1
- UNMODLJJNIJIBD-OTBVPMHJSA-N Vinglycinate sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 UNMODLJJNIJIBD-OTBVPMHJSA-N 0.000 description 1
- 229950009832 Vinleurosine Drugs 0.000 description 1
- 229960002166 Vinorelbine tartrate Drugs 0.000 description 1
- GBABOYUKABKIAF-IWWDSPBFSA-N VinorelbineTartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 description 1
- 208000008383 Wilms Tumor Diseases 0.000 description 1
- 229950005561 ZANOTERONE Drugs 0.000 description 1
- 101710010406 ZBP14 Proteins 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- FYQZGCBXYVWXSP-STTFAQHVSA-N Zinostatin stimalamer Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1OC1C/2=C/C#C[C@H]3O[C@@]3([C@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(C)C=CC2=C(C)C=C(OC)C=C12 FYQZGCBXYVWXSP-STTFAQHVSA-N 0.000 description 1
- 229950009233 Zinostatin stimalamer Drugs 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2S)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-BVTJJHQYSA-N [(1S,2Z,7S,10Z,12R,13R,15S)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C/C(=O)O[C@@H](C)CCC\C=C/[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-BVTJJHQYSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2R,3S)-2-[(2S,3R)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- YJTVZHOYBAOUTO-URBBEOKESA-N [(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl octadecyl hydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OCCCCCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 YJTVZHOYBAOUTO-URBBEOKESA-N 0.000 description 1
- VUPBDWQPEOWRQP-YDYCAPBPSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R)-3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino Chemical compound O([C@H]1[C@@H]([C@H](O)[C@H](N)[C@H](C)O1)O)C(C(O)C=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN)NC(=O)C(C(O)C)NC(=O)CC(O)C(C)NC(=O)C([C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C VUPBDWQPEOWRQP-YDYCAPBPSA-N 0.000 description 1
- ZHHIHQFAUZZMTG-BSVJBJGJSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C ZHHIHQFAUZZMTG-BSVJBJGJSA-N 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8R,9S,13S,14S,17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- XASGSSXPZXRXFL-UHFFFAOYSA-L [1-(aminomethyl)cyclohexyl]methanamine;platinum(2+);sulfate Chemical compound [Pt+2].[O-]S([O-])(=O)=O.NCC1(CN)CCCCC1 XASGSSXPZXRXFL-UHFFFAOYSA-L 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N [3-[4-(3-methylsulfonyloxypropanoyl)piperazin-1-yl]-3-oxopropyl] methanesulfonate Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- ASQRQYODAQUVBR-UHFFFAOYSA-L [4-(aminomethyl)oxan-4-yl]methanamine;cyclobutane-1,1-dicarboxylate;platinum(2+) Chemical compound [Pt+2].NCC1(CN)CCOCC1.[O-]C(=O)C1(C([O-])=O)CCC1 ASQRQYODAQUVBR-UHFFFAOYSA-L 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] N-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DEXPIBGCLCPUHE-UISHROKMSA-N acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 DEXPIBGCLCPUHE-UISHROKMSA-N 0.000 description 1
- IAGMBSXKAGFBJT-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC(O)=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO IAGMBSXKAGFBJT-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000001772 anti-angiogenic Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 102000025417 antigen binding proteins Human genes 0.000 description 1
- 108091000829 antigen binding proteins Proteins 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045696 antineoplastic drugs Podophyllotoxin derivatives Drugs 0.000 description 1
- 230000003078 antioxidant Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- 201000008271 atypical teratoid rhabdoid tumor Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229930014667 baccatin III Natural products 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229960004649 calcipotriene Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- LSUTUUOITDQYNO-UHFFFAOYSA-N calphostin C Chemical compound C=12C3=C4C(CC(C)OC(=O)C=5C=CC=CC=5)=C(OC)C(O)=C(C(C=C5OC)=O)C4=C5C=1C(OC)=CC(=O)C2=C(O)C(OC)=C3CC(C)OC(=O)OC1=CC=C(O)C=C1 LSUTUUOITDQYNO-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229930016259 castanospermine Natural products 0.000 description 1
- 101700018328 ccdB Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 201000009047 chordoma Diseases 0.000 description 1
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 150000004814 combretastatins Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture media Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000001054 cortical Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 108010041566 cypemycin Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229950006614 cytarabine ocfosfate Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- SVJSWELRJWVPQD-UHFFFAOYSA-L disodium;2-[[4-[2-(2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]amino]pentanedioate Chemical compound [Na+].[Na+].C1NC=2NC(N)=NC(=O)C=2CC1CCC1=CC=C(C(=O)NC(CCC([O-])=O)C([O-])=O)C=C1 SVJSWELRJWVPQD-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229940017743 dromostanolone propionate Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229960002759 eflornithine Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002357 endometrial Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000008228 ependymoblastoma Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- HWMJAPURZLIYQA-JPFZJSEDSA-L ethanolate;(Z)-3-oxo-1-phenylbut-1-en-1-olate;titanium(4+) Chemical compound [Ti+4].CC[O-].CC[O-].CC(=O)\C=C(/[O-])C1=CC=CC=C1.CC(=O)\C=C(/[O-])C1=CC=CC=C1 HWMJAPURZLIYQA-JPFZJSEDSA-L 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl N-[4-[[(2R,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N ethyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N ethyl N-bis(2,2-dimethylaziridin-1-yl)phosphorylcarbamate Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N ethylene glycol monomethyl ether Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 231100001004 fissure Toxicity 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 102000034387 fluorescent proteins Human genes 0.000 description 1
- 108091006031 fluorescent proteins Proteins 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108010075381 growth inhibitory factor Proteins 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;N-methyl-N-[4-[(7-methyl-3H-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- 230000000222 hyperoxic Effects 0.000 description 1
- 201000006866 hypopharynx cancer Diseases 0.000 description 1
- 230000002267 hypothalamic Effects 0.000 description 1
- 230000002631 hypothermal Effects 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003344 immunostimulant Effects 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000001024 immunotherapeutic Effects 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003795 iobenguane (123I) Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 229960002618 lenograstim Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 101710007041 let-363 Proteins 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229950007056 liarozole Drugs 0.000 description 1
- 201000006721 lip cancer Diseases 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cells Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 230000000116 mitigating Effects 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229950010088 mitopodozide Drugs 0.000 description 1
- 230000000394 mitotic Effects 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 229940035032 monophosphoryl lipid A Drugs 0.000 description 1
- 230000001002 morphogenetic Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000005445 natural product Substances 0.000 description 1
- 229930014626 natural products Natural products 0.000 description 1
- CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- MAZYQGHSTXUZJF-ZBRHGPMOSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](O)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@]5(C)C[C@H](C[C@@H](O5)CC4=C3C3=O)N(C)C)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 MAZYQGHSTXUZJF-ZBRHGPMOSA-N 0.000 description 1
- 230000001453 nonthrombogenic Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000008042 ovarian germ cell cancer Diseases 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N oxophosphanyl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000001991 pathophysiological Effects 0.000 description 1
- URWXJEHYXOTXBD-UHFFFAOYSA-N pentazocine Chemical compound C1=CN=NN=NN=C1 URWXJEHYXOTXBD-UHFFFAOYSA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 229960003820 pentosan polysulfate sodium Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 230000003169 placental Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- FXSKHQLAUMGYJK-UHFFFAOYSA-J platinum(4+);propan-2-amine;dichloride;dihydroxide Chemical compound [OH-].[OH-].[Cl-].[Cl-].[Pt+4].CC(C)N.CC(C)N FXSKHQLAUMGYJK-UHFFFAOYSA-J 0.000 description 1
- 201000008199 pleuropulmonary blastoma Diseases 0.000 description 1
- 108010049948 plitidepsin Proteins 0.000 description 1
- 239000003600 podophyllotoxin derivative Substances 0.000 description 1
- 229920000740 poly(D-lysine) polymer Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000003806 protein tyrosine phosphatase inhibitor Substances 0.000 description 1
- 230000002797 proteolythic Effects 0.000 description 1
- 210000001938 protoplasts Anatomy 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 239000000784 purine nucleoside phosphorylase inhibitor Substances 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
- 230000001850 reproductive Effects 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 230000000284 resting Effects 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 201000000582 retinoblastoma Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229950003733 romurtide Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Inorganic materials [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- DCQXTYAFFMSNNH-UHFFFAOYSA-M sodium;2-[bis(2-hydroxyethyl)amino]ethanol;acetate Chemical compound [Na+].CC([O-])=O.OCCN(CCO)CCO DCQXTYAFFMSNNH-UHFFFAOYSA-M 0.000 description 1
- HZOREEUASZHZBI-UHFFFAOYSA-M sodium;2-phenylacetate Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1 HZOREEUASZHZBI-UHFFFAOYSA-M 0.000 description 1
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M sodium;6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylate Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- 210000004215 spores Anatomy 0.000 description 1
- 108060007889 sspB Proteins 0.000 description 1
- 108060007895 sspP Proteins 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 231100000803 sterility Toxicity 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 108091007018 stromelysin Proteins 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000008205 supratentorial primitive neuroectodermal tumor Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 229930003522 swainsonine Natural products 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 108010021891 tallimustine Proteins 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 201000009365 thymic carcinoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- FQYFLFUZRJOLBC-UHFFFAOYSA-N titanocene Chemical compound C12C3C4C5C1[Ti]16782345C2C7C6C1C82 FQYFLFUZRJOLBC-UHFFFAOYSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 101700028090 torI Proteins 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000000700 tracer Substances 0.000 description 1
- 230000002463 transducing Effects 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-M triacetate(1-) Chemical compound CC(=O)CC(=O)CC([O-])=O ILJSQTXMGCGYMG-UHFFFAOYSA-M 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000004450 types of analysis Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
Abstract
Disclosed is a use of an ?????-ECD binding agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the alleviation of vascular leak syndrome in a subject in need thereof.
Description
METHODS FOR TREATING VASCULAR LEAK SYNDROME AND CANCER
REFERENCE TO RELATED APPLICATION
This application claims priority to US. Provisional Application Serial No. 61/546,748
filed October 13, 2011 and to US. Provisional Application Serial No. 61/546,697 filed October
13, 2011. The entire content of US. Provisional Application Serial No. 6l/546,748 and US.
Provisional Application Serial No. ,697 is incorporated herein by reference.
INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED
ELECTRONICALLY
Incorporated by reference in its entirety is a computer-readable sequence listing
ted concurrently herewith and identified as follows: One 92 KB ASCII (Text) file named
6-33l560_Seq_Listing_ST25,” created on r 15, 2012, at 11:52 am.
FIELD
Methods for treating cancer, preventing metastasis and vascular leak syndrome by
administration of a HPTPB inhibitor.
BACKGROUND
Vascular leak syndrome (VLS) is characterized by nsion, peripheral edema and
hypoalbuminemia. VLS can occur as a side effect of illness ally illnesses due to
pathogens, inter alia, viruses and bacteria. Vascular leak cates the healing process and
can itself be a direct result of certain therapies. For example, patients suffering from malignant
renal carcinoma are given Interleukin-2 (IL-2) to help boost their immune system. However, this
treatment must be withdrawn in many ts due to the onset of severe VLS well before the full
course of treatment can be administered. VLS cts the doses of IL-2 which can be
administered to humans and, in some cases, necessitates the cessation of therapy before the
therapy is maximally effective.
VLS is characterized by an se in vascular permeability accompanied by
extravasation of fluids and proteins resulting in interstitial edema and organ failure.
Manifestations of VLS e fluid retention, increase in body weight, peripheral edema, pleural
and pericardial effusions, ascites, anasarca and, in severe form, signs of pulmonary and
cardiovascular failure. Symptoms are highly le among patients and the causes are poorly
understood. Endothelial cell modifications or damage are thought to be important is vascular
leak. The pathogenesis of endothelial cell (EC) damage is complex and can involve activation or
damage to ECs and leukocytes, release of nes and of inflammatory mediators, alteration in
cell-cell and cell-matrix adhesion and in cytoskeleton function.
One of the most frightening aspects of cancer is its ability to spread, or metastasize.
Initially, cancer cells are found grouped together thereby forming one or more tumors. After
formation of the primary tumor, cancer cells can gain the ability to separate from the original
tumor and travel to other areas of the body. Lung cancer cells that take up in the liver and form
tumors are still lung cancer cells. Thus, the propensity for one particular form of cancer to
metastasize is dependent on many s, including type of cancer; r, the overall process
of how cells begin the process of metastasis is still not completely understood.
If a single localized tumor is discovered before it has had a chance to metastasize,
then the prognosis of patient survival is higher. This is because the tumor can be effectively
d or yed by radiation or chemotherapy. There is, therefore, a difference between
tumor growth and metastasis of the tumor cells; the first does not always lead to the other.
Cancers that have asized, however, are ult to cure because of extent to which they
have spread throughout the body.
In order to metastasize, a cancer cell must break away from its tumor and invade
either the circulatory or lymph system. The free cells are then carried to a new location where
they establish themselves. Although the body has natural safeguards that prevent cell from
ing after being detached from their natural location, some cancer cells have the ability to
overcome these safeguards. Therefore, if metastasis is stopped or icantly reduced, the
extent of cancer can be determined and subsequently treated. As such, a follow up treatment to
cancer therapy wherein a tumor has been excised or radiation/chemotherapy has been used,
would be the treatment of the patient to an etastasizing agent. There is a long felt need for
methods of preventing cancer cell metastasis.
The growth of primary tumors also presents a challenge to treatment. If the growth of
a primary tumor goes unchecked, the l tumor can grow to a size that adversely effects organ
function at the primary site and in nearby tissues. Metastasis of the primary tumor are also more
likely if the primary tumor’s growth is uncontrolled. There is a need for methods of slowing or
preventing tumor growth.
During the course of antiviral and antibacterial infections, patients can develop
vascular leak that is induced as result of the initial infection. There is now a long felt need for a
method of preventing vascular leak due to viral or bacterial infection, and for providing methods
of sing the survival of humans or other mammals infected with one or more pathogens. In
addition, there is a long felt need for a method of preventing vascular leakage due to certain
anticancer drugs or other anticancer therapies such that the stration of anticancer drugs or
anticancer therapies can be given to humans or other mammals for a longer course of treatment
or therapy.
SUMMARY
The present disclosure provides methods for treating a patient having ar leak
syndrome sing administering to the patient a composition comprising an ive amount
of an ECD binding agent or a pharmaceutically acceptable salt thereof.
Also provided are s for treating a t having ar leak syndrome
comprising administering to the patient, a composition comprising an effective amount of an
HPTPB-ECD binding agent or a pharmaceutically acceptable salt f, and one or more
pharmaceutically acceptable excipient.
The present disclosure provides for s of treating vascular leak wherein the
patient being treated is suffering from an inflammatory disease or condition, trauma, shock, adult
respiratory distress syndrome, acute lung injury, or sepsis comprising administering to the
patient, a ition comprising an effective amount of an HPTPB-ECD binding agent or a
pharmaceutically acceptable salt thereof.
] The present disclosure also provides for methods of treating vascular leak wherein the
patient being treated is suffering from an inflammatory disease or condition, trauma, shock, adult
respiratory distress syndrome, acute lung injury, or sepsis comprising stering to the
patient, a composition comprising an effective amount of an HPTPB-ECD binding agent or a
pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipient.
] Another method provided by the present disclosure, is a method for determining the
course of treatment for a patient suffering from vascular leak syndrome, comprising:
a) administering to a patient a composition comprising an effective amount of an HPTPB-ECD
binding agent; b) ring the level of angiopoietin-2 present in the t during the course
of ent; and c) discontinuing treatment when the angiopoietin-2 level returns to Within a
normal range.
] A further method provided by the present disclosure is a method for treating cancer in
a patient, comprising administering to a patient a composition comprising an effective amount of
an HPTPB-ECD binding agent or a pharmaceutically acceptable salt thereof.
A further method provided by the present is a method for ng cancer in a t,
comprising administering to a patient a composition comprising an effective amount of an
HPTPB-ECD binding agent or a pharmaceutically acceptable salt thereof, and a ceutically
acceptable excipient.
Still another method provided by the present disclosure is a method for preventing
metastasis in a patient with cancer, by administering to a patient a ition comprising an
effective amount of an HPTPB-ECD binding agent or a pharmaceutically acceptable salt thereof.
Still another method provided by the present disclosure is a method for preventing
metastasis in a patient with cancer, by administering to a patient a composition sing an
effective amount of an HPTPB-ECD binding agent or a pharmaceutically acceptable salt f,
and a pharmaceutically acceptable excipient.
In the s of the present disclosure, HPTPB-ECD binding agents include, but are
not limited to antibodies, proteins, peptides, aptamers, peptibodies, adnectins, or nucleic acids,
that binds to the extracellular portion of HPTPB.
BRIEF DESCRIPTION OF THE FIGURES
Fig. 1. The monoclonal antibody R15E6 recognizes endogenous HPTPB on
endothelial Cells. (Panel A) Endothelial cell lysates are immunoprecipitated with a control
antibody (Lane 1), with R15E6 (Lane 2), or with a mixture of anti-Tie2 and anti-VEGFR2
antibodies (Lane 3). precipitates are resolved by SDS-PAGE, transferred to a PVDF
ne and probed by western blot with a mixture of R15E6, anti-Tie2 and anti-VEGFR2
antibodies. A single major high molecular weight band consistent with HPTPB is seen with
R15E6 (Lane 2), and not with the control antibody (Lane 1), or the mixture of anti-Tie2 and anti-
VEGFR2 (Lane 3). (Panel B) elial cells are ted to FACS is with R15E6
(white peak) or a no primary antibody control (black peak). The robust shift in fluorescence
indicates that R15E6 binds to HPTPB on the surface of intact elial cells.
Fig. 2 The monoclonal antibody R15E6 enhances Tie2 Receptor Activation in
HUVECs. Tie2 activation is measured in human endothelial cells as described in Example 4.
R15E6 dose dependently enhances both basal and Angl-induced Tie2 activation.
Fig. 3. Is a graphical representation of the mean area of choroidal neovascularization
in C57BL/6 mice 14 days post laser treatment in eyes treated with intravitreal ion of lug or
2pg of an anti-VE-PTP ellular domain antibody in one eye versus similar treatment of the
fellow eye with vehicle.
Fig. 4. Shows the mean area (mmz) of l neovascularization in C57BL/6 mice on
day P17 after containment in a 75% oxygen atmosphere from P5 to P12 and intravitreal ion
of an anti-VE-PTP extracellular domain antibody at P12 when the mice were returned to room
air.
Fig. 5. Show representative fluorescent raphs of mouse retinas in the oxygen-
induced retinopathy model after intravitreal injection of vehicle or 2 ug of an anti-VE-PTP
extracellular domain antibody.
Fig. 6. Shows the mean area (mmz) of retinal neovascularization in C57BL/6 mice on
day P17 after containment in a 75% oxygen atmosphere from P5 to P12 followed by return to
room air on P12 with subcutaneous administration of 1 mg/kg of an anti-VE-PTP extracellular
domain antibody on days P12, 14 and 16.
Fig. 7. Shows the mean area (mmz) of retinal neovascularization in C57BL/6 mice on
day P17 after containment in a 75% oxygen atmosphere from P5 to P12 follow by return to room
air on P12 with subcutaneous administration of 2 mg/kg of an anti-VE-PTP extracellular domain
antibody on days P12, 14 and 16.
DETAILED DESCRIPTION
General Definitions
In this specification and in the claims that follow, reference will be made to a number
of terms, which shall be defined to have the following meanings:
The term "HPTPB-ECD binding agent" and “specific binding agent” are used
interchangeably herein and refer to a molecule that ically binds to the extracellular portion
of HPTPB, and variants and derivatives thereof, as defined herein, that inhibits the Tie2
dephosphorylase activity of HPTPB.
“Agent” as used herein refers to an “HPTPB binding agent” or unless otherwise noted.
fically binds ECD” refers to the ability of a specific binding agent of
the present invention to recognize and bind to an epitope of the extracellular domain of HPTPB
with higher affinity than to other related and/or unrelated molecules. Specific binding agents
preferentially bind to HPTPB in a complex e of proteins and/or macromolecules. The
specific binding agent is preferably selective for HPTPB. “Selective” means that the agent has
icantly greater activity toward HPTPB compared with other d and/or unrelated
les, not that it is completely inactive with regard to other molecules. For example, a
selective agent may show 10-fold, lOO-fold, or lOOO-fold selectivity toward HPTPB than to other
related or unrelated molecules.
The term “anti-HPTPB-ECD antibodies” refers to antibodies or antibody fragments
that bind to the extracellular domain of HPTPB. PTPB-ECD antibodies are a type of
HPTPB-ECD binding agent as defined herein.
The term “VE-PTP” refers to the mouse ortholog of HPTPB.
All percentages, ratios and proportions herein are by , unless otherwise
specified. All temperatures are in degrees Celsius (0C) unless otherwise specified.
Ranges may be sed herein as from one particular value to another particular
value, the endpoints are included in the range. For example for the range from “lmg to 50mg”
includes the specific values lmg and 50mg. The antecedent ” indicates that the values are
approximate. For example for the range from “about lmg to about 50mg” indicates that the
values are imate values. Additionally, when such a range is expressed, the range includes
the range “from lmg to 50mg”. It will be further understood that the endpoints of each of the
ranges are significant both in on to the other nt, and independently of the other
endpoint. For example the range “from lmg to 50mg”, includes the range “from 30mg to 40mg.”
] As used herein, the term “in combination” refers to the use of more than one
prophylactic and/or therapeutic agent. The use of the term “in combination” does not restrict the
order in which lactic and/or therapeutic agents are stered to a t. A first
lactic or therapeutic agent can be administered prior to (e. g., 1 minute, 5 minutes, 15
minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours,
72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks
before), concomitantly with, or subsequent to (e. g., 1 minute, 5 minutes, 15 minutes, 30 minutes,
45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1
week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) the
administration of a second lactic or therapeutic agent to a t which had, has, or is
susceptible to a disorder. The prophylactic or therapeutic agents are administered to a patient in a
sequence and within a time interval such that the agent of the present disclosure can act er
with the other agent to provide an increased benefit than if they were administered otherwise.
Any additional prophylactic or therapeutic agent can be administered in any order with the other
additional prophylactic or therapeutic agents
“Effective amount” means an amount of an active agent or combination of agents
effective to ameliorate or prevent the symptoms, or g the survival of the patient being
treated. An effective amount may vary according to factors known in the art, such as the disease
state, age, sex, and weight of the human or animal being treated. Although particular dosage
regimes may be described in examples herein, a person skilled in the art would appreciated that
the dosage regime may be altered to provide optimum therapeutic response. For example,
several divided doses may be administered daily or the dose may be proportionally reduced as
indicated by the exigencies of the therapeutic ion. In addition, the compositions of this
disclosure can be administered as frequently as necessary to achieve a therapeutic amount.
Determination of a therapeutically effective amount is well within the capabilities of those skilled
in the art, especially in light of the detailed disclosure provided herein.
As used herein the term “inhibit” or “inhibiting” refers to a statistically significant and
measurable reduction in ty, preferably a reduction of at least about 10% versus control,
more preferably a reduction of about 50% or more, still more ably a reduction of about
80% or more.
As used herein the term “increase” or “increasing” refers to a statistically icant
and measurable increase in activity, preferably an increase of at least about 10% versus control,
more preferably an se of about 50% or more, still more preferably an se of about
80% or more.
“HPTP beta” or “HPTPB” are used interchangeably herein and are abbreviations for
human protein tyrosine phosphatase beta.
As used herein, “subject” means an individual. Thus, the “subject” can include
domesticated animals (e.g., cats, dogs, etc.), livestock (e. g., cattle, , pigs, sheep, goats,
etc.), laboratory animals (e. g., mouse, rabbit, rat, guinea pig, etc.), and birds. “Patient” can also
include a mammal, such as a primate or a human. “Subject” and “patient” are used
interchangeably herein. Preferably the t is a human.
By “reduce” or other forms of the word, such as “reducing” or “reduction,” is meant
ng of an event or characteristic (e. g., vascular leakage). It is understood that this is
typically in relation to some standard or expected value, in other words it is relative, but that it is
not always necessary for the rd or ve value to be referred to.
The terms “treatment”, “treating”, “treat” and the like, refer to obtaining a desired
pharmacologic and/or physiologic effect such as mitigating a disease or a disorder in a host
and/or reducing, inhibiting, or eliminating a particular characteristic or event associated with a
disorder (e.g., vascular leak). Thus, the term "treatment" includes, preventing a disorder from
ing in a host, particularly when the host is predisposed to acquiring the disease, but has not
yet been diagnosed with the disease; inhibiting the disorder; and/or alleviating or reversing the
disorder. Insofar as the methods of the present invention are directed to preventing disorders, it
is understood that the term "prevent" does not require that the disease state be completely
ed. Rather, as used herein, the term preventing refers to the ability of the skilled n to
identify a tion that is susceptible to disorders, such that administration of the HPTPB-ECD
binding agents of the disclosure may occur prior to onset of a disease. The term does not imply
WO 56240
that the disease state is completely avoided.
] As used herein, the term “cancer treatment” means any treatment for cancer known in
the art including, but not limited to, chemotherapy and radiation therapy.
As used herein, the term “cancer treatment” means any treatment for cancer known in
the art including, but not limited to, chemotherapy and radiation therapy.
Throughout the description and claims of this specification the word ise” and
other forms of the word, such as “comprising” and “comprises,” means including but not limited
to, and is not intended to exclude, for example, other additives, components, integers, or steps.
] As used in the description and the appended claims, the singular forms 4‘ 77 4‘
a, an,” and
“the” include plural referents unless the t clearly dictates otherwise. Thus, for example,
reference to “a composition” includes mixtures of two or more such compositions.
“Optional” or “optionally” means that the subsequently described event or
circumstance can or cannot occur, and that the description includes instances where the event or
circumstance occurs and instances where it does not.
“Specifically binds HPTPB” refers to the ability of an agent of the present ion to
ize and bind to an epitope of the extracellular domain of HPTPB with higher ty than
to the other related and/or unrelated molecules. The agent is preferably selective for HPTPB.
“Specific” means that the agent has significantly greater activity toward HPTPB compared with
other related and/or unrelated molecules, not that it is completely inactive with regard to other
molecules. For example, a selective agent may show 10-fold, ld, or old selectivity
toward HPTPB than to other related or unrelated molecules.
The term “epitope” refers to any portion of any le capable of being recognized
by and bound by an agent at one or more of the agent’s antigen binding regions. Epitopes
y consist of distinct e groupings such as amino acids, sugars, lipids, phosphoryl, or
sulfonyl, and, in certain embodiments, may have specific three dimensional structural
characteristics, and/or specific charge characteristics. Epitopes as used herein may be
conformational or linear.
“Peptibody” is a molecule comprising an antibody Fc domain attached to at least one
peptide. The production of peptibodies is generally described in W02002/24782.
ent” refers to a portion of an agent. A fragment may retain the desired
biological activity of the agent and may be considered to be an agent itself. For example a
ted protein in which the amino terminus and/or carboxy terminus and/or an internal amino
acid residue is deleted is a fragment of the protein and an Fab of an immunoglobulin molecule is
a fragment of the immunoglobulin. Such fragments may also be connected to r molecule
by way of a direct connection (e. g. a peptide or ide bond) or by way of a .
“Protein” is used herein interchangeably with e and polypeptide.
Peptides of the present invention include, but are not limited to amino acid sequences
having from about 3 to about 75 amino acids, or from about 5 to about 50 amino acids, or from
about 10 to about 25 amino acids. Peptides may be naturally occurring or artificial amino acid
sequences .
A protein of the invention may be obtained by methods well known in the art, for
example, using standard direct peptide synthesizing techniques such as via solid-phase synthesis.
If the gene sequence is known or can be deduced then the protein may be ed by standard
recombinant s. The proteins may be isolated or purified in a variety of ways known to
one d in the art. Standard purification methods include precipitation with salts,
ophoretic, chromatographic techniques and the like.
“Derivatives” include those binding agents that have been chemically modified in
some manner distinct from insertion, deletion, or substitution variants. For example, wherein the
binding agent is a protein, the carboxyl terminus may be capped with an amino group, such as
NHZ.
In some ments one or more molecules are linked together to form the agent.
For example antibody fragments may be connected by a linker. In general the chemical structure
of the linker is not critical as it serves ily as a space. In one ment the linker is
made of amino acids linked together by way of peptide bonds. In another embodiment the linker
is a non-peptide linker such as a non-sterically hindering C1-C6 alkyl group. In another
embodiment the linker is a PEG linker. It will further be appreciated that the linker can be
inserted in a number of locations on the molecule.
Variants of an agent are included within the scope of the present invention. “Variant”
or “Variants” as used herein means an agent having a protein or nucleotide ce which is
substantially similar to the protein or nucleotide sequence of the non-variant agent and which
shares a similar activity of the non-variant agent. A n or nucleotide ce may be
altered in various ways to yield a variant encompassed by the present invention, including
substitutions, deletions, tions, insertions and other modifications. s for such
manipulations are well known in the art. See, for example, Current Protocols in Molecular
Biology (and updates) Ausubel et al., Eds (1996), John Wiley and Sons, New York: Methods in
Molecular Biology, Vol. 182, In vitro Mutagenesis Protocols, 2nd Edition, Barman Ed. (2002),
Humana Press), and the nces cited therein. For example, variants e es and
polypeptides n amino acid residues are inserted into, deleted from and/or substituted into
the known amino acid sequence for the binding agent. In one embodiment, the substitution of the
amino acid is conservative in that it minimally alters the biochemical ties of the variant. In
other embodiments, the variant may be an active fragment of a full-length protein, a chemically
modified n, a protein modified by addition of affinity or epitope tags, or fluorescent or
other labeling moieties, whether accomplished by in vivo or in vitro enzymatic treatment of the
protein, by chemical modification, or by the synthesis of the protein using modified amino acids.
Fusions ns are also contemplated herein. Using known methods, one of skill in
the art would be able to make fusion proteins of the proteins of the invention; that, while different
from native form, may be useful. For example, the fusion partner may be a signal (or leader)
polypeptide ce that nslationally or post-translationally directs transfer of the protein
from its site of synthesis to another site (e. g., the yeast alpha-factor leader). Alternatively, it may
be added to facilitate purification or identification of the protein of the invention (e. g., poly-His,
Flag peptide, or fluorescent proteins).
Standard techniques may be used for recombinant DNA, oligonucleotide synthesis,
and tissue culture and transformation (e. g., electroporation, lipofection). Enzymatic reactions and
purification ques may be med according to manufacturer's specifications or as
commonly accomplished in the art or as described herein. The techniques and procedures are
generally performed ing to conventional methods known in the art and as described in
various general and more specific references that are cited and discussed throughout the present
specification. Unless specific definitions are provided, the nomenclature ed in connection
with, and the laboratory ures and techniques of, analytical chemistry, synthetic organic
chemistry, and medicinal and pharmaceutical chemistry described herein are those known and
commonly used in the art. rd techniques may be used for chemical syntheses, chemical
analyses, ceutical preparation, formulation, ry, and treatment of patients.
Sequence Listing
Table l.
SEQ ID NO:1 Full length Human HPTPB nucleotide sequence (X54131)
SEQ ID NO 2 Full length Human HPTPB amino acid sequence (P23467)
SEQ ID NO 3 Extracellular Portion of Human HPTPB with (His)6Gly Tag
SEQ ID NO:4 Extracellular Portion of Human HPTPB
SEQ ID NO:5 Full length mouse VE-PTP nucleotide sequence (AY077755)
SEQ ID NO:6 Full length mouse VE-PTP amino acid sequence (AAL75813)
SEQ ID NO:7 Extracellular portion of mouse VE-PTP amino acid sequence
HPTPB-ECD binding agents
Agents useful in the present invention include, but are not limited to, antibodies,
proteins, darpins, peptides, aptamers, ins, peptibodies, or nucleic acids that bind
specifically to the extracellular n of HPTPB and inhibit at least one atase actiVity of
HPTPB. As used herein, “phosphatase ty” includes enzymatic actiVity and biologic actiVity
where biological actiVity is measured by assessing Tie2 phosphorylation.
Agents useful in the t invention further include: antibodies, or antigen binding
nts thereof which bind to the extracellular n of HPTPB wherein the antibody or
antigen-binding fragment inhibits at least one phosphatase actiVity of HPTPB. These agents
include monoclonal and polyclonal antibodies. An agent may be a fragment of an antibody,
wherein the fragment comprises the heavy and light chain variable regions, or the fragment is an
F(ab’)2, or the fragment is a dimer or trimer of an Fab, FV, scFV, or a dia-, tria-, or tetrabody
derived from the antibody.
For e, the agent may be, without limitation, an antibody or antibody fragment
that binds the extracellular portion of HPTPB; or in particular an dy that binds an FN3
repeat of HPTPB, or more ically an antibody that binds the first FN3 repeat of HPTPB.
Agents r include: the onal antibody R15E6 which is described in U.S.
Pat. No. 7,973,142, which is hereby incorporated in its entirety. (The mouse hybridoma, Balbc
spleen cells (B cells) which may be used to produce the antibody are deposited with an
Type Culture Collection (ATCC), P.O. Box 1549, Manassas, Va. 20108 USA on 4 May 2006,
assigned ATCC No. PTA-7580) (Referred to herein as R15E6)), antibodies having the same or
substantially the same biological characteristics of R15E6; antibody nts of R15E6,
wherein the nt ses the heavy and light chain variable regions; an F(ab’)2 of R15E6;
dimers or trimers of an Fab, Fv, scFv; and dia-, tria-, or tetrabodies derived from R15E6.
In particular, an agent suitable for use in the present invention is an antibody,
antibody fragment, variant or derivatives thereof, either alone or in combination with other amino
acid sequences, provided by known techniques. Such techniques include, but are not limited to
enzymatic cleavage, chemical cleavage, peptide synthesis or recombinant techniques. The
invention further embraces derivative agents, e. g. peptibodies.
Thus, one embodiment of an HPTPB-ECD binding agent is an antibody, another
embodiment is a protein, yet another embodiment is a peptide, and another embodiment is a
darpin, another embodiment is an aptamer, another ment is a peptibody, still another
embodiment is an adnectin, another embodiment is a nucleic acid. In some embodiments the
HPTPB-ECD binding agent is an monoclonal antibody, or is a polyclonal antibody. In particular
embodiments, the HPTPB-ECD binding agent is an antibody fragment that is capable of binding
to HPTPB-ECD. ably the HPTPB-ECD binding agent is an antibody, or an antibody
fragment, including but not limited to, an F(ab’)2, an Fab, a dimer of an Fab, an Fv, a dimer of an
Fv, a scFv, a dimer of a scFv, a dimer an Fab, an Fv, a dimer of an Fv, a scFv, a dimer of a scFv,
a trimer of an Fab, a trimer of an Fv, a trimer of a scFv, minibodies, a diabody a triabody, a
tetrabody, a linear antibody, a protein, a peptide, an aptamer, a peptibody, an adnectin, or a
c acid, that binds to the extracellular portion of HPTPB. In certain embodiments the
HPTPB-ECD binding agent is and F(ab’)2 of a monoclonal antibody. In some embodiments the
HPTPB-ECD binding agent comprises a plurality of HPTPB-ECD binding sites, for e
where the HPTPB-ECD binding agent is an intact antibody or an F(ab’)2, or a dimer of an Fab, or
a trimer of an Fab. For example, in some ments an ΗΡΤΡβ-ECD binding agent is able
to bind to two ΗΡΤΡβ molecules simultaneously at the same or different epitope, thereby
bringing the two ΗΡΤΡβ les into close proximity with one and other. In other
embodiments the ΗΡΤΡβ-ECD binding agent is able to bind to three ΗΡΤΡβ les
simultaneously at the same or different epitope, thereby bringing the three ΗΡΤΡβ molecules
into close proximity with one and other. In another embodiment, the ΗΡΤΡβ-ECD binding
agent is the monoclonal antibody produced by hybridoma cell line ATCC No. PTA-7580. In
yet another embodiment, the ΗΡΤΡβ-ECD binding agent is an antigen binding nt of
the monoclonal antibody produced by hybridoma cell line ATCC No. PTA-7580. In still
another embodiment, the ΗΡΤΡβ-ECD binding agent is an dy having the same or
substantially the same biological characteristics the monoclonal dy produced by
hybridoma cell line ATCC No. PTA-7580 or an antigen g fragment thereof.
Any of the ments of ΗΡΤΡβ-ECD binding agents disclosed in the
present application, may be covalently or non-covalently conjugated to a vehicle. The term
"vehicle" refers to a molecule that affects a biological property of an agent. For example, a
vehicle may prevent degradation, and/or increase half-life, tion, reduce ty, reduce
immunogenicity, or increase biological activity of the agent. Exemplary vehicles include, but
are not limited to, Fc domains of immunoglobulins; polymers, for e: polyethylene
glycol (PEG), sine, dextran; lipids; cholesterol groups (such as a steroid);
carbohydrates, dendrimers, oligosaccharides, or peptides that binds to a salvage receptor. In
some embodiments the vehicle is polyethylene glycol (PEG), in other embodiments the
vehicle is polylysine, in yet other embodiments the vehicle is dextran, in still other
embodiments the vehicle is a lipid.
Water soluble polymer attachments, such as polyethylene ,
polyoxyethylene , or polypropylene glycol, as described U.S. Pat. Nos. 4,640,835,
4,496,689, 144, 4,670,417, 4,791,192, and 4,179,337, which are incorporated herein in
their entirety. Still other useful polymers known in the art include monomethoxypolyethylene
glycol, dextran, cellulose, or other ydrate based polymers, poly-(N-vinyl
pyrrolidone) -polyethylene glycol, propylene glycol homopolymers, a polypropylene
oxide/ethylene oxide co-polymer, polyoxyethylated polyols (e.g., glycerol) and polyvinyl
alcohol, as well as mixtures of these polymers. Particularly preferred are peptibodies
covalently modified with polyethylene glycol (PEG) subunits. Water soluble polymers may
be bonded at specific positions, for example at the amino terminus of the peptibodies, or
randomly attached to one or more side chains of the
polypeptide. The use of PEG for ing the eutic capacity for agents, e.g. peptibodies,
and for humanized antibodies in particular, is described in US. Pat. No. 6,133,426. The
invention also contemplates derivatizing the peptide and/or vehicle portion of the agents. Such
derivatives may improve the solubility, absorption, biological half-life, and the like of the agents.
The es may alternatively eliminate or attenuate any undesirable side-effect of the agents
and the like.
] The term "antibody" (Ab) as used herein includes monoclonal antibodies, polyclonal
antibodies, multi-specific antibodies (e. g. bispecific antibodies), single chain antibodies, e. g.,
antibodies from llama and camel, antibody fragments, e. g., variable regions and/or constant
region fragments, so long as they exhibit a desired biological activity, e. g., antigen-binding
ty. The term "immunoglobulin" (Ig) is used hangeably with "antibody" herein.
An “antigen binding fragment” as used herein is a fragment of an agent that binds to a
portion of HPTPB and ts at least one phosphatase activity of HPTPB.
The basic four-chain antibody unit is a tetrameric glycoprotein composed of
two identical light (L) chains and two identical heavy (H) chains (an IgM antibody consists of 5
of the basic heterotetramer units along with an additional polypeptide called J chain, and
therefore n 10 antigen binding sites, while secreted IgA antibodies may polymerize to form
polyvalent lages comprising 2-5 of the basic 4-chain units along with J chain). In the case
of IgGs, the four-chain unit is generally about 150 kilo Daltons (kDa). Each L chain is linked to
an H chain by one covalent disulfide bond, while the two H chains are linked to each other by
one or more disulfide bonds depending on the H chain isotype. Each H and L chain also has
regularly spaced hain disulfide bridges. Each H chain has at the N-terminus, a variable
domain (VH) followed by three constant domains (CH) for each of the alpha and gamma chains
and four CH domains for mu and epsilon isotypes. Each L chain has at the N-terminus, a variable
domain (VL) followed by a constant domain (CL) at its other end. The VL is aligned with the VH
and the CL is aligned with the first constant domain of the heavy chain (CH1). ular amino
acid residues are believed to form an interface between the light chain and heavy chain variable
domains. The pairing of a VH and VL together forms a single antigen-binding site. For the
structure and properties of the different classes of antibodies, see, e. g., Basic and Clinical
Immunology, 8th edition, Daniel P. Stites, Abba I. Terr and Tristram G. Parslow (eds.), Appleton
& Lange, 1994, page 71 and Chapter 6.
] The L chain from any vertebrate s may be assigned to one of two clearly
distinct types, called kappa and lambda, based on the amino acid sequences of their nt
domains. ing on the amino acid sequence of the constant domain of their heavy chains
(CH), immunoglobulins may be assigned to different classes or isotypes. There are five classes of
immunoglobulins: IgA, IgD, IgE, IgG and IgM, having heavy chains designated alpha, delta,
epsilon, gamma and mu, tively. The gamma and alpha classes are further divided into
subclasses on the basis of relatively minor differences in CH sequence and function, e.g., humans
express the following subclasses: IgGl, IgG2, IgG3, IgG4, IgAl and IgA2.
s of the Camelidae family, e.g., llama, camel, and dromedaries, contain a
unique type of antibody, that are devoid of light chains, and further lack the CH1 domain
(Muyldermans, 8., Rev. Mol. Biotechnol., 74, 277-302 (2001)). The variable region of these
heavy chain antibodies are termed VHH or VHH, and tute the smallest available intact
antigen binding fragment (15 kDa) derived from a functional immunoglobulin.
The term "variable" refers to the fact that certain segments of the variable s
differ extensively in sequence among dies. The V domain mediates antigen binding and
defines specificity of a particular antibody for its antigen. r, the variability is not evenly
distributed across the llO-amino acid span of the variable domains. Instead, the V regions consist
of relatively invariant stretches called framework regions (FR) of 15-30 amino acids separated by
shorter regions of extreme variability called "hypervariable regions" that are each 9-12 amino
acids long. The variable domains of native heavy and light chains each comprise four FRs,
y adopting a B-sheet configuration, connected by three hypervariable regions, which form
loops connecting, and in some cases forming part of, the B-sheet structure. The hypervariable
regions in each chain are held together in close proximity by the FRs and, with the hypervariable
regions from the other chain, contribute to the formation of the antigen-binding site of antibodies.
The nt domains are not involved directly in g an antibody to an antigen, but exhibit
various effector functions, such as participation of the antibody in antibody ent cellular
cytotoxicity (ADCC).
The term "hypervariable region" when used herein refers to the amino acid residues of
an antibody which are responsible for antigen-binding. The hypervariable region generally
comprises amino acid residues from a "complementarity determining " or "CDR" (e.g.
around about residues 24-34 (Ll), 50-56 (L2) and 89-97 (L3) in the VL, and around about 1-35
(H1), 50-65 (H2) and 95-102 (H3) in the VH; Kabat et al., Sequences of Proteins of
Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda,
Md. (1991)) and/or those residues from a "hypervariable loop".
The term "monoclonal antibody" as used herein refers to an dy obtained from a
population of substantially homogeneous antibodies, i.e., the individual antibodies comprising
the tion are identical except for possible naturally occurring mutations that may be present
in minor amounts. In contrast to polyclonal antibody preparations which include different
antibodies directed against ent epitopes, each onal antibody is directed against a
single epitope, i.e., a single antigenic determinant. In addition to their specificity, the monoclonal
dies are advantageous in that they may be synthesized uncontaminated by other antibodies.
The modifier "monoclonal" is not to be construed as requiring production of the antibody by any
particular method. For example, the monoclonal antibodies useful in the t invention may
be prepared by the hybridoma methodology or may be made using recombinant DNA methods in
ial, eukaryotic animal or plant cells (see, e.g., U.S. Pat. No. 4,816,567). The "monoclonal
antibodies" may also be isolated from phage antibody libraries, using the available ques,
e.g., Clackson et al., Nature, Vol. 352, pp. 624-628 (1991).
The monoclonal dies herein e ric" antibodies in which a portion of
the heavy and/or light chain is identical with or homologous to corresponding sequences in
antibodies derived from a particular species or ing to a particular antibody class or
subclass, while the remainder of the chain(s) is identical with or homologous to corresponding
sequences in antibodies derived from another species or ing to another antibody class or
subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological
activity (see U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81, 6851-
6855 (1984)).
An "antibody nt" comprises a portion of a eric antibody, preferably the
antigen binding or variable region of the intact antibody. Examples of antibody fragments include
Fab, Fab‘, F(ab')2, dimers and trimers of Fabs, Fv, scFv, minibodies; dia-, tria-, and tetrabodies;
linear antibodies (See Hudson et al., Nature Med. 9, 129-134 (2003)).
"Fv" is the minimum antibody fragment which contains a complete antigen binding
site. This fragment consists of a dimer of one heavy- and one light-chain variable region domain
in tight, non-covalent association. From the folding of these two s emanate six
hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid
residues for antigen binding and confer antigen binding specificity to the dy. However,
even a single variable domain (or half of an Fv comprising only three CDRs specific for an
n) has the ability to recognize and bind antigen, and are therefore included in the definition
of Fv.
A single-chain variable fragment (scFv) is a fusion protein of the variable regions of
the heavy (VH) and light chains (VL) of immunoglobulins, connected with a short linker peptide
of ten to about 25 amino acids. The linker is usually rich in glycine for lity, as well as
serine or threonine for solubility, and can either connect the N-terminus of the VH with the C-
terminus of the VL, or vice versa. This protein retains the specificity of the original
globulin, despite removal of the constant regions and the introduction of the linker.
Divalent (or bivalent) single-chain variable fragments (di-scFvs, bi-scFvs) can be
engineered by g two scFvs. This can be done by producing a single peptide chain with two
VH and two VL regions, yielding tandem scFvs. Another possibility is the creation of scFvs with
linker peptides that are too short for the two variable regions to fold together (about five amino
, forcing scFvs to dimerize. This type is known as diabodies. Diabodies have been shown to
have dissociation constants up to 40-fold lower than corresponding scFvs, meaning that they
have a much higher affinity to their target. Consequently, diabody drugs could be dosed much
lower than other therapeutic antibodies and are capable of highly specific targeting of tumors in
vivo. Still shorter linkers (one or two amino acids) lead to the ion of s, so-called
dies or tribodies. Tetrabodies are known and have been shown to exhibit an even higher
affinity to their targets than diabodies.
The term "humanized dy" or "human antibody" refers to antibodies which
comprise heavy and light chain variable region sequences from a non-human species (e. g., a
mouse) but in which at least a portion of the VH and/or VL sequence has been altered to be more
"human-like", i.e., more similar to human germline variable sequences. One type of humanized
dy is a afted dy, in which human CDR sequences are introduced into non-
human VH and VL sequences to e the corresponding nonhuman CDR sequences. Means for
making chimeric, CDR-grafted and humanized antibodies are known to those of ordinary skill in
the art (see, e.g., U.S. Pat. Nos. 4,816,567 and 5,225,539). One method for making human
antibodies employs the use of transgenic animals, such as a transgenic mouse. These transgenic
animals contain a substantial portion of the human antibody producing genome inserted into their
own genome and the 's own endogenous antibody production is rendered deficient in the
production of antibodies. Methods for making such transgenic animals are known in the art. Such
transgenic animals may be made using XenoMouse.RTM. technology or by using a "minilocus"
approach. Methods for making XenoMice.RTM. are described in U.S. Pat. Nos. 6,162,963,
6,150,584, 6,114,598 and 6,075,181. Methods for making enic animals using the
"minilocus" approach are described in U.S. Pat. Nos. 5,545,807, 5,545,806, 5,625,825, and W0
93/12227.
Humanization of a non-human antibody has become routine in recent years, and is
now within the knowledge of one skilled in the art. Several companies provide services to make a
humanized antibody, e.g., Xoma, Aries, Medarex, PDL, and Cambridge dy Technologies.
Humanization protocols are extensively described in technical literature, e.g., Kipriyanov and Le
Gall, Molecular Biotechnol., Vol. 26, pp. 39-60 , Humana Press, , N.J.; Lo,
Methods Mol. Biol., Vol. 248, pp. 9 (2004), Humana Press, Totowa, N.J.; Wu et al., J.
Mol. Biol., 294, pp. 151-162 (1999).
In certain embodiments, antibodies useful in the t invention may be expressed
in cell lines other than hybridoma cell lines. Sequences encoding particular antibodies may be
used for transformation of a le mammalian host cell by known methods for introducing
polynucleotides into a host cell, including, for example packaging the polynucleotide in a virus
(or into a viral vector) and transducing a host cell with the virus (or ), or by transfection
procedures known in the art, as exemplified by U.S. Pat. Nos. 4,399,216, 4,912,040, 4,740,461
and 4,959,455. The ormation ure used may depend upon the host to be transformed.
Methods for introduction of heterologous polynucleotides into mammalian cells are known in the
art and include; but are not limited to, dextran-mediated transfection, calcium phosphate
precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation
of the polynucleotide(s) in liposomes, mixing nucleic acid with positively-charged lipids, and
direct microinjection of the DNA into nuclei.
A nucleic acid molecule encoding the amino acid sequence of a heavy chain constant
region, a heavy chain variable region, a light chain constant , or a light chain le
region of an antibody, or a fragment thereof in a suitable ation if desired, is/are inserted
into an riate expression vector using standard ligation techniques. The antibody heavy
chain or light chain constant region may be appended to the C-terminus of the appropriate
variable region and is ligated into an expression vector. The vector is lly selected to be
functional in the particular host cell employed (i.e., the vector is compatible with the host cell
machinery such that amplification of the gene and/or expression of the gene may occur). For a
review of expression vectors, see Methods l. Vol. 185 (Goeddel, ed.), 1990, Academic
Press.
Identification of specific g agents
Suitable selective binding agents may be fied using a variety of techniques
known in the art. For example candidate agents can be screened for binding to HPTPB, and
screened for activity. Generally the candidate agents will first be screened for binding and those
that show selective binding will then be screened to determine ability to t the HPTPB-
mediated phorylation of Tie2. In some cases however the candidate agents may be first
screened in vitro for activity.
Determination of binding activity
The selection of a suitable assay for use in fication of a specific binding agent
depends on the nature of the candidate agent to be screened. One of skill in the art would be able
to choose the appropriate assays for the particular candidate agent.
For example, where the ates are antibodies or odies which comprises an
Fc moiety, FACS analysis as described in Example 3 B allows the candidate agent to be selected
based on its ability to bind to cells which express HPTPB. The cell may endogenously express
HPTPB or may be genetically engineered to express HPTPB.
For other candidate agents such as aptamers, other techniques are known in the art.
For example, aptamers which ically bind to HPTPB can be selected using a technique
known as SELEX matic evolution of ligands by exponential enrichment) which selects
ic aptamers h repeated rounds of in vitro selection.
Determination of inhibitor activity by Western blot
As exemplified in Example 4, in one suitable assay HUVECs are cultured in serumfree
media in the presence or absence of various concentrations of candidate agent and lysates of
the cells are prepared, immunoprecipitated with a Tie2 antibody, resolved by polyacrylamide gel
2012/060273
electrophoresis and transferred to a PVDF membrane. Membrane-bound immunoprecipitated
proteins are then serially western blotted with an antiphosphotyrosine antibody to quantify Tie2
phosphorylation followed by a Tie2 antibody to quantify total Tie2. Tie2 phosphorylation is
expressed as the ratio of the anti-phosphotyrosine signal over the total Tie2 signal. Greater levels
of the anti-phosphotyrosine signal indicate greater HPTPB inhibition by the candidate agent.
Candidate agents that can be screened include, but are not d to, libraries of
known agents, including natural products, such as plant or animal extracts, ically active
molecules including proteins, es including but not d to members of random peptide
libraries and atorial chemistry derived molecular y made of D- or L-configuration
amino acids, dies including, but not limited to, polyclonal, onal, chimeric, human,
single chain antibodies, Fab, F(ab)2 and Fab expression library fragments and eptiope-binding
fragments thereof).
] As used herein “antibody nts” include, but are not limited, to an F(ab’)2, a
dimer or trimer of an Fab, Fv, scFv, or a dia-, tria-, or tetrabody derived from an antibody.
Throughout this application, various publications are referenced. The disclosures of
these publications in their entireties are hereby incorporated by reference into this application in
order to more fully describe the state of the art.
The vascular endothelium lines the inside of all blood s, forming a non-
thrombogenic surface that controls the entry and exit of plasma and white blood cells to and from
the bloodstream. The quiescent endothelium has turnover rates of months to years, and
proliferates only following angiogenic activation. The loss of endothelial quiescence is a
common feature of conditions such as ation, atherosclerosis, restenosis, angiogenesis and
various types of vasculopathies.
Vasculogenesis and angiogenesis are down-regulated in the healthy adult and are,
except for the organs of the female reproductive system, almost exclusively associated with
ogy when angiogenesis is induced by microenvironmental factors such as hypoxia or
inflammation. These pathological processes associated with, or induced by, angiogenesis include
diseases as diverse as cancer, psoriasis, macular degeneration, ic retinopathy, thrombosis,
and inflammatory disorders including arthritis and atherosclerosis. r, in certain instances
insufficient angiogenesis can lead to diseaeses such as ischemic heart disease and pre-eclampsia.
The quiescent vascular endothelium forms a tight barrier that controls the passage of
plasma and cells from the bloodstream to the underlying tissues. Endothellial cells adhere to
each other h junctional transmembrane proteins that are linked to specific intracelllar
structural and signaling xes. The endothelial layer can undergo a transition from the
resting state to the active state wherein activation of the endothelium results in the expression of
adhesion molecules. This endothelium activation is a prerequisite for initiating angiogensesis,
ation and inflammation associated diseases.
Tie-2, a receptor-like tyrosine kinase exclusively expressed in endothelial cells that
controls endothelial differentiation. Tie-2 binds and is activated by the stimulatory ligand
oeitin-l (Ang-l) which promotes autophosphorylation of the Tie-2 receptor leading to a
cascade of events that results in stabilization of vascular structures by promoting endothelial cell
ity and preventing basement membrane dissolution. As such, Tie-2 activation is a method
for attenuating leaking ature by maintaining a quiescent, intact vascular endothelium. Tie-
2 activation is inhibited by Ang-2, which ts Ang-l antagonism by competitively g to
Tie-2 and thus blocking phosphorylation of Tie-2. ed levels of Ang-2 have been found to
be associated with inflammatory diseases, inter alia, sepsis, lupus, inflammatory bowel disease
and metastatic diseases such as cancer.
During periods of high Ang-2 levels, fissures or breaks in the endothelium form
which results in vascular leak syndrome. Vascular leak syndrome results in hreatening
effects such as tissue and pulmonary edema. For many disease states elevated Ang-2 levels are
clear s that a disease state or condition exists. Once a disease state has been resolved, the
Ang-l/Ang-2 e returns and the ar endothelium is stabilized. In conditions wherein
the normal balance between Ang-l and Ang-2 has been disrupted, the disclosed agents have been
found to amplify Tie-2 signaling by inhibiting phorylation of phosphorylated Tie-2 via
inhibition of Human Protein Tyrosine Phosphatase-[3 (HPTP-B). In addition, the disclosed agents
can be used in varying amounts to increase the Tie-2 signaling in a very controlled manner, and
to ore titrate the level of Tie-2 ication.
The present disclosure provides methods for treating a patient having vascular leak
syndrome comprising administering to the patient a composition comprising effective amount of
an HPTPB-ECD binding agent or a pharmaceutically acceptable salt thereof. The compositions of
the present disclosure may also comprise one or more pharmaceutically acceptable excipients.
Disclosed herein, are compositions comprising an HPTPB-ECD g agent
wherein the compositions are useful for ent of the disclosed conditions, illness, injuries,
courses of treatment, cellular treatments and the like.
In one embodiment, the method comprises treating vascular leak in a patient wherein
the patient suffers from an inflammatory disease or condition which comprises administering to
the patient a composition comprising an effective amount of an HPTPB-ECD binding agent.
Another embodiment is a method of treating a patient suffering from a physical trauma
comprising administering to the patient a composition sing an effective amount of an
HPTPB-ECD binding agent. In a ular embodiment the trauma is surgical trauma. In one
embodiment the method is a method of treating a patient ing from shock comprising
administering to the patient a composition comprising an effective amount of an HPTPB-ECD
binding agent.
ular embodiments include post-hemorrhagic shock, or post-traumatic shock or
septic shock. The present disclosure also provides for a method of treating a patient suffering
from adult respiratory distress syndrome by administering to the patient a composition
comprising an effective amount of an HPTPB-ECD binding agent. Another embodiment is a
method of treating a patient with an acute lung injury comprising administering to the patient a
composition comprising an effective amount of an HPTPB-ECD binding agent. Cancer
metastasis and bacterial and Viral infections are d below.
In some ments an HPTPB-ECD binding agent is administered prophylactically
to stabilize the patient’s ature prior to an event that places the patient at risk for vascular
leak. In one embodiment the HPTPB-ECD binding agent is administered lactically to
stabilize the patient’s vasculature prior to y. Still another embodiment is a method of
preventing vascular leak syndrome in a patient wherein an effective amount of an HPTPB-ECD
binding agent is administered to the patient prior to undergoing herapy. Another
ment is a method of treating a patient at risk of shock comprising administering to the
patient an effective amount of an HPTPB-ECD binding agent.
] The disclosed HPTPB-ECD binding agents can be used to prevent, abate, minimize,
control, and/or lessen tumor metastasis in humans and animals. The disclosed HPTPB-ECD
binding agents can also be used to slow the rate of primary tumor growth. As such, the agents
disclosed herein can be stered as part of a combination therapy with one or more drugs or
other pharmaceutical agents. When used as part of the combination therapy, the se in
metastasis and reduction in primary tumor growth afforded by the disclosed agents allows for a
more ive and efficient use of any pharmaceutical or drug therapy being used to treat the
patient. In addition, control of metastasis by the disclosed agent affords the subject a greater
ability to concentrate the disease in one location.
Thus, one embodiment of the present disclosure is a method of treating cancer in a
patient comprising administering a composition comprising an effective amount of an HPTPB-
ECD binding agent or a pharmaceutically acceptable salt thereof. r embodiment is a
method of preventing metastasis in a patient suffering from cancer sing administering a
ition comprising an effective amount of an HPTPB-ECD binding agent or a
pharmaceutically acceptable salt thereof. Yet another embodiment is a method of minimizing
tumor metastasis in a patient suffering from cancer comprising administering a composition
comprising an effective amount of an ECD binding agent or a pharmaceutically
acceptable salt thereof. Disclosed herein are methods for preventing metastasis of malignant
tumors or to reduce the rate of tumor growth. Thus, another embodiment is a method of treating
a patient diagnosed with a malignant tumor comprising stering to the patient a
composition comprising an effective amount of an HPTPB-ECD binding agent or a
pharmaceutically acceptable salt thereof. Another embodiment is a method of preventing
metastasis in a patient diagnosed with a malignant tumor comprising administering to the t
a composition comprising an effective amount of an HPTPB-ECD binding agent or a
pharmaceutically acceptable salt thereof. Yet r embodiment is a method of reducing the
rate of tumor growth in a t diagnosed with a tumor comprising administering to the patient
a composition comprising an effective amount of an HPTPB-ECD binding agent or a
ceutically acceptable salt thereof.
The following are non-limiting examples of cancers that can be treated by the
disclosed methods and compositions: leukemia, for example, chronic myelogenous leukemia;
acute lymphoblastic leukemia, acute childhood myeloid leukemia; adult acute d ia,
hairy cell ia; lymphoma, for example, Burkitt’s lymphoma, Hodgkin’s lymphoma, non-
Hodgkin’s lymphoma, cutaneous t-cell lymphoma, central nervous system ma;
astrocytomas, for example, cerebellar ytoma, childhood astrocytoma, pilocytic
astrocytoma, diffuse astrocytoma, stic astrocytoma, gliomas, oligodendroglioma, cerebral
astrocytoma visual pathway glioma and alamic glioma, brain stem glioma, visual pathway,
hypothalamic glioma, cerebral astrocytoma/malignant ; carcinoma, for example, thymoma
carcinoma, thymic carcinoma, squamous cell carcinoma, skin carcinoma, Merkel cell carcinoma,
adrenocortical carcinoma, cortical carcinoma, basal cell oma; sarcoma, for e,
rhabdomyosarcoma sarcoma, Ewing sarcoma, Kaposi sarcoma, soft tissue sarcoma, uterine
sarcoma, osteosarcoma, malignant fibrous histiocytoma of the bone; ix cancer;
extrahepatic bile duct cancer; bladder cancer; bone ; salivary gland cancer; brain tumor;
childhood central nervous system atypical teratoid/rhabdoid tumor; central nervous system
embryonal tumors; craniopharyngioma; ependymoblastoma; ependymoma; medulloblastoma;
medulloepithelioma; pineal parenchymal tumors of intermediate differentiation; supratentorial
primitive neuroectodermal tumors and lastoma; brain and spinal cord tumors; breast
cancer; bronchial tumors; carcinoid tumor; gastrointestinal carcinoid tumor; l nervous
system embryonal tumors; cervical ; chordoma, childhood; chronic roliferative
disorders; colon ; colorectal cancer; craniopharyngioma; extragonadal germ cell tumor;
testicular germ cell tumor; retinoblastoma; gallbladder cancer; gastric (stomach) cancer;
intestinal carcinoid tumor; gastrointestinal stromal tumor (gist); extracranial germ cell
tumor; gestational trophoblastic tumor; glioblastoma; head and neck cancer; hepatocellular (liver)
cancer; Langerhans cell histiocytosis; hypopharyngeal cancer; islet cell tumors; kidney (renal
cell) cancer; laryngeal ; lip and oral cavity cancer; liver cancer; non-small cell lung cancer;
small-cell lung cancer; mesothelioma; metastatic squamous neck cancer with occult primary;
mouth cancer; childhood multiple endocrine neoplasia syndrome; multiple myeloma/plasma cell
neoplasm; mycosis fungoides; myelodysplastic syndromes; multiple myeloma;
myeloproliferative disorders, chronic; nasal cavity and paranasal sinus cancer; lastoma;
oral cancer; ryngeal cancer; ovarian cancer, for example, ovarian epithelial cancer, ovarian
germ cell tumor, ovarian low malignant ial tumor; pancreatic cancer; islet cell tumors;
papillomatosis; thyroid cancer; parathyroid cancer; penile cancer; esophageal cancer; pharyngeal
cancer; nasopharyngeal cancer; pheochromocytoma; pineal parenchymal tumors; pituitary tumor;
plasma cell neoplasm/multiple myeloma; pleuropulmonary blastoma; prostate cancer; rectal
; renal cell (kidney) cancer; renal pelvis and ureter cancer; Sézary syndrome; skin cancer
(nonmelanoma); skin cancer (melanoma); intraocular melanoma; malignant melanoma, small
intestine ; metastatic squamous neck cancer; stomach (gastric) cancer; testicular cancer;
throat cancer; transitional cell cancer of the renal pelvis and ureter; ional trophoblastic
tumor; al cancer; uterine cancer, endometrial; vaginal cancer; vulvar cancer; WaldenstrOm
macroglobulinemia; and Wilms tumor.
8] The HPTPB-ECD g agents can be administered in combination with one or
more chemotherapeutic agent.
A “chemotherapeutic agent” or “chemotherapeutic compound” is a chemical
compound useful in the treatment of cancer. Chemotherapeutic cancer agents that can be used in
combination with an HPTPB-ECD binding agent disclosed herein, e but are not limited to,
mitotic inhibitors (vinca alkaloids). These include stine, stine, vindesine and
NavelbineTM (vinorelbine-5'-noranhydroblastine). In yet other embodiments, chemotherapeutic
cancer agents e topoisomerase I inhibitors, such as camptothecin compounds. As used
herein, “camptothecin compounds” include CamptosarTM (irinotecan HCL), HycamtinTM
(topotecan HCL) and other compounds derived from camptothecin and its ues. Another
category of chemotherapeutic cancer agents that may be used in the methods and compositions of
the present disclosure are podophyllotoxin derivatives, such as etoposide, teniposide and
mitopodozide. The present disclosure further encompasses other chemotherapeutic cancer agents
known as alkylating agents, which alkylate the genetic al in tumor cells. These include
Without limitation cisplatin, cyclophosphamide, nitrogen mustard, trimethylene
thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, uracil mustard, chlomaphazin
and dacarbazine. The present disclosure asses antimetabolites as chemotherapeutic
agents. Examples of these types of agents include cytosine arabinoside, fluorouracil,
methotrexate, mercaptopurine, azathioprime and procarbazine. An additional category of
chemotherapeutic cancer agents that may be used in the methods and compositions of the t
disclosure include antibiotics. Examples e Without tion doxorubicin, cin,
dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C and daunomycin. There are
numerous liposomal formulations commercially available for these nds. The present
disclosure further encompasses other chemotherapeutic cancer agents including Without
limitation anti-tumor dies, dacarbazine, azacytidine, amsacrine, lan, VM-26,
ifosfamide, taxol and its derivatives, L—asparaginase, mitoxantrone, IF-2, gemcitabine, erlotinib,
doxil, irinortecan and bevacizumab.
Other anti-cancer agents that can be used in combination with the disclosed HPTPBECD
binding agent include, but are not limited to: acivicin, aclarubicin, acodazole hydrochloride,
acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate,
aminoglutethimide, anastrozole, anthramycin, asperlin, idine, azetepa, azotomycin,
batimastat, benzodepa, bicalutamide, bisantrene hloride, bisnafide dimesylate, bizelesin,
cin sulfate, brequinar sodium, bropirimine, omycin, calusterone, caracemide,
carbetimer, carboplatin, carubicin hydrochloride, carzelesin, cedefingol, cirolemycin, cladribine,
crisnatol mesylate, cytarabine, daunorubicin hydrochloride, decitabine, dexormaplatin,
dezaguanine, dezaguanine mesylate, diaziquone, docetaxel, doxorubicin hydrochloride,
droloxifene, droloxifene citrate, dromostanolone propionate, duazomycin, edatrexate, eflornithine
hydrochloride, elsamitrucin, enloplatin, ate, epipropidine, epirubicin hydrochloride,
zole, esorubicin hydrochloride, estramustine, estramustine phosphate sodium, etanidazole,
etoposide phosphate, etoprine, fadrozole hydrochloride, fazarabine, fenretinide, floxuridine,
fludarabine ate, flurocitabine, fosquidone, ecin sodium, gemcitabine hydrochloride,
hydroxyurea, idarubicin hydrochloride, ilmofosine, interleukin 2 ding recombinant
interleukin 2, or rIL2), interferon alfa-2a, interferon alfa-2b, interferon alfa-nl, interferon alfa-n3,
interferon beta-la, interferon lb, iproplatin, irinotecan hydrochloride, lanreotide acetate,
letrozole, leuprolide acetate, liarozole hydrochloride, lometrexol sodium, lomustine, losoxantrone
hydrochloride, masoprocol, maytansine, mechlorethamine hydrochloride, megestrol acetate,
melengestrol acetate, menogaril, rexate sodium, metoprine, meturedepa, mitindomide,
mitocarcin, mitocromin, mitogillin, mitomalcin, mitosper, mitotane, mitoxantrone hydrochloride,
mycophenolic acid, nocodazole, nogalamycin, ormaplatin, an, paclitaxel, pegaspargase,
peliomycin, pentamustine, peplomycin sulfate, perfosfamide, pipobroman, piposulfan,
ntrone hydrochloride, plicamycin, plomestane, porfimer sodium, porfiromycin,
prednimustine, procarbazine hydrochloride, cin, puromycin hydrochloride, pyrazofurin,
riboprine, rogletimide, ol, safingol hydrochloride, semustine, simtrazene, sparfosate
sodium, sparsomycin, spirogermanium hydrochloride, spiromustine, spiroplatin, streptonigrin,
streptozocin, sulofenur, talisomycin, lan sodium, tegafur, teloxantrone hloride,
temoporfin, teroxirone, testolactone, thiamiprine, thioguanine, thiotepa, tiazofurin, tirapazamine,
toremifene citrate, trestolone e, triciribine phosphate, trimetrexate, trimetrexate
glucuronate, triptorelin, tubulozole hydrochloride, uredepa, vapreotide, verteporfin, Vinblastine
sulfate, Vincristine sulfate, Vindesine sulfate, Vinepidine e, Vinglycinate sulfate, Vinleurosine
sulfate, Vinorelbine tartrate, Vinrosidine sulfate, idine sulfate, vorozole, atin,
zinostatin, zorubicin hydrochloride. Other ancer drugs include, but are not limited to: 20-
dihydroxyVitamin D3, 5-ethynyluracil, abiraterone, aclarubicin, acylfulvene,
adecypenol, adozelesin, aldesleukin, ALL-TK nists, altretamine, ambamustine, amidox,
amifostine, aminolevulinic acid, cin, amsacrine, anagrelide, anastrozole, andrographolide,
angiogenesis inhibitors, antagonist D, antagonist G, antarelix, anti-dorsalizing morphogenetic
n-l, antiandrogen, prostatic carcinoma, antiestrogen, antineoplaston, aphidicolin glycinate,
apoptosis gene modulators, sis regulators, apurinic acid, ara-CDP-DL-PTBA, arginine
deaminase, asulacrine, atamestane, atrimustine, axinastatin l, axinastatin 2, axinastatin 3,
azasetron, in, azatyrosine, baccatin III tives, balanol, batimastat, BCR/ABL
antagonists, benzochlorins, benzoylstaurosporine, beta lactam tives, beta-alethine,
betaclamycin B, betulinic acid, bFGF inhibitor, bicalutamide, bisantrene, bisaziridinylspermine,
bisnafide, bistratene A, bizelesin, breflate, bropirimine, budotitane, buthionine sulfoximine,
calcipotriol, calphostin C, canarypox IL-2, capecitabine, carboxamide-amino-triazole,
carboxyamidotriazole, CaRest M3, CARN 700, cartilage d inhibitor, esin, casein
kinase inhibitors (ICOS), castanospermine, in B, cetrorelix, ns, chloroquinoxaline
sulfonamide, cicaprost, cis-porphyrin, cladribine, clomifene analogues, clotrimazole, collismycin
A, collismycin B, combretastatin A4, combretastatin analogue, conagenin, crambescidin 816,
crisnatol, cryptophycin 8, cryptophycin A derivatives, curacin A, cyclopentanthraquinones,
cycloplatam, cypemycin, cytarabine ocfosfate, cytolytic factor, atin, dacliximab,
decitabine, dehydrodidemnin B, deslorelin, dexamethasone, dexifosfamide, oxane,
dexverapamil, diaziquone, in B, didox, diethylnorspermine, dihydroazacytidine,
dihydrotaxol, 9-, dioxamycin, diphenyl spiromustine, docetaxel, docosanol, dolasetron,
doxifluridine, droloxifene, dronabinol, mycin SA, ebselen, ecomustine, edelfosine,
edrecolomab, eflornithine, elemene, emitefur, epirubicin, epristeride, estramustine analogue,
estrogen agonists, estrogen antagonists, azole, etoposide phosphate, exemestane, fadrozole,
fazarabine, fenretinide, filgrastim, finasteride, flavopiridol, flezelastine, fluasterone, bine,
fluorodaunorunicin hydrochloride, forfenimex, formestane, fostriecin, stine, gadolinium
texaphyrin, gallium nitrate, galocitabine, ganirelix, gelatinase tors, gemcitabine, glutathione
inhibitors, hepsulfam, heregulin, hexamethylene bisacetamide, hypericin, ibandronic acid,
idarubicin, idoxifene, idramantone, ilmofosine, ilomastat, imidazoacridones, imiquimod,
immunostimulant peptides, insulin-like growth factor-1 receptor tor, interferon agonists,
iobenguane, iododoxorubicin, ipomeanol, 4-, iroplact, irsogladine, isobengazole,
isohomohalicondrin B, itasetron, jasplakinolide, kahalalide F, lamellarin-N triacetate, lanreotide,
ycin, lenograstim, lentinan sulfate, leptolstatin, letrozole, leukemia inhibiting ,
yte alpha interferon, leuprolide+estrogen+progesterone, leuprorelin, levamisole, liarozole,
linear polyamine analogue, lipophilic disaccharide peptide, lipophilic platinum compounds,
lissoclinamide 7, lobaplatin, lombricine, lometrexol, lonidamine, losoxantrone, lovastatin,
loxoribine, lurtotecan, lutetium texaphyrin, lysofylline, lytic es, maitansine, mannostatin A,
marimastat, masoprocol, maspin, matrilysin inhibitors, matrix oproteinase inhibitors,
menogaril, merbarone, meterelin, ninase, metoclopramide, MIF inhibitor, mifepristone,
miltefosine, mirimostim, mismatched double stranded RNA, mitoguazone, mitolactol, mitomycin
analogues, fide, mitotoxin fibroblast growth factor-saporin, mofarotene, molgramostim,
monoclonal dy, human chorionic gonadotrophin, monophosphoryl lipid A+myobacterium
cell wall sk, mopidamol, multiple drug resistance gene inhibitor, multiple tumor suppressor 1-
based therapy, mustard anticancer agent, mycaperoxide B, cterial cell wall extract,
myriaporone, N-acetyldinaline, N-substituted benzamides, nafarelin, nagrestip,
naloxone+pentazocine, napavin, naphterpin, nartograstim, nedaplatin, nemorubicin, neridronic
acid, neutral endopeptidase, nilutamide, cin, nitric oxide modulators, nitroxide
antioxidant, nitrullyn, O6-benzylguanine, octreotide, okicenone, oligonucleotides, onapristone,
ondansetron, ondansetron, oracin, oral cytokine r, ormaplatin, osaterone, oxaliplatin,
oxaunomycin, paclitaxel, paclitaxel analogues, paclitaxel derivatives, palauamine,
palmitoylrhizoxin, pamidronic acid, panaxytriol, fene, parabactin, pazelliptine,
pegaspargase, peldesine, pentosan polysulfate sodium, pentostatin, pentrozole, ron,
perfosfamide, perillyl l, phenazinomycin, phenylacetate, phosphatase inhibitors, picibanil,
pilocarpine hydrochloride, pirarubicin, piritrexim, in A, placetin B, plasminogen tor
inhibitor, platinum x, platinum compounds, um-triamine complex, porfimer sodium,
porfiromycin, prednisone, propyl ridone, glandin J2, proteasome inhibitors, protein
A-based immune modulator, protein kinase C inhibitor, protein kinase C inhibitors, microalgal,
protein tyrosine phosphatase inhibitors, purine nucleoside phosphorylase inhibitors, purpurins,
pyrazoloacridine, pyridoxylated hemoglobin polyoxyethylene conjugate, raf antagonists,
raltitrexed, ramosetron, ras famesyl protein transferase inhibitors, ras tors, ras-GAP
inhibitor, retelliptine demethylated, rhenium Re 186 etidronate, rhizoxin, ribozymes, RII
retinamide, imide, rohitukine, romurtide, roquinimex, rubiginone B l, ruboxyl, safingol,
saintopin, SarCNU, sarcophytol A, sargramostim, Sdi l mimetics, semustine, senescence derived
inhibitor 1, sense oligonucleotides, signal transduction inhibitors, signal transduction tors,
single chain antigen binding protein, sizofiran, xane, sodium borocaptate, sodium
phenylacetate, solverol, somatomedin binding protein, sonermin, sparfosic acid, spicamycin D,
spiromustine, splenopentin, spongistatin l, squalamine, stem cell inhibitor, stem-cell division
inhibitors, stipiamide, stromelysin inhibitors, sulfinosine, superactive tive intestinal
peptide antagonist, suradista, suramin, swainsonine, synthetic aminoglycans, tallimustine,
tamoxifen methiodide, tauromustine, tazarotene, tecogalan sodium, tegafur, tellurapyrylium,
telomerase inhibitors, temoporfin, temozolomide, tetrachlorodecaoxide, tetrazomine,
lastine, thiocoraline, thrombopoietin, thrombopoietin mimetic, thymalfasin, thymopoietin
or agonist, thymotrinan, thyroid stimulating hormone, tin ethyl rpurin, tirapazamine,
titanocene ride, topsentin, toremifene, totipotent stem cell factor, ation inhibitors,
tretinoin, triacetyluridine, triciribine, rexate, triptorelin, tropisetron, turosteride, tyrosine
kinase tors, tyrphostins, UBC inhibitors, ubenimex, urogenital sinus-derived growth
inhibitory factor, urokinase receptor antagonists, vapreotide, variolin B, vector system,
erythrocyte gene therapy, velaresol, veramine, verdins, verteporfin, vinxaltine, vitaXin, vorozole,
zanoterone, atin, zilascorb, and zinostatin stimalamer. In one embodiment, the ancer
drug is 5-fluorouracil or leucovorin.
Anti-angiogenic agents are also useful in the treatment of cancer. Anti-angiogenic
agents are well known to those of skill in the art. Suitable anti-angiogenic agents for use in the
s and compositions of the present disclosure include anti-VEGF antibodies, including
humanized and chimeric antibodies, anti-VEGF aptamers and antisense oligonucleotides. Other
known inhibitors of angiogenesis include angiostatin, endostatin, interferons, interleukin 1
(including 0t and B) interleukin 12, retinoic acid, and tissue inhibitors of metalloproteinase-l and
metalloproteinase-2. (TIMP-1 and -2). Small molecules, including omerases such as
razoxane, a topoisomerase II inhibitor with anti-angiogenic activity, can also be used.
2] One embodiment of the disclosure is a method for treating a patient diagnosed with a
carcinoma, comprising administering to the patient a composition comprising an effective
amount of an HPTPB-ECD binding agent. Yet another ment is a method for treating a
patient diagnosed with a carcinoma, sing administering to the patient a composition
comprising an effective amount of an HPTPB-ECD binding agent in combination with an
effective amount of a chemotherapeutic agent, wherein the HPTPB-ECD binding agent and
chemotherapeutic agent are administered together or in any order.
One embodiment of the disclosure is a method for preventing or reducing metastasis
in a patient diagnosed with a carcinoma, comprising administering to the patient a composition
comprising an effective amount of an HPTPB-ECD binding agent. Yet r embodiment is a
method for preventing or reducing metastasis in a patient diagnosed with a oma,
comprising administering to the patient a composition comprising an effective amount of an
HPTPB-ECD binding agent in combination with an ive amount of a chemotherapeutic
agent, wherein the ECD binding agent and chemotherapeutic agent are administered
er or in any order.
In yet another embodiment of the disclosure is a method for treating a patient
diagnosed with a sarcoma, comprising administering to the patient a composition comprising an
effective amount of an HPTPB-ECD binding agent. Yet another embodiment is a method for
treating a patient diagnosed with a sarcoma, comprising administering to the patient a
composition comprising an effective amount of an HPTPB-ECD binding agent in combination
with an effective amount of a chemotherapeutic agent, wherein the HPTPB-ECD binding agent
and the chemotherapeutic agent are stered together or in any order.
Yet another embodiment of the sure is a method for ting or reducing
metastasis in a patient diagnosed with a sarcoma, comprising administering to the patient a
composition comprising an effective amount of an HPTPB-ECD g agent. Yet another
embodiment is a method for preventing or ng metastasis in a patient diagnosed with a
sarcoma, comprising administering to the patient a composition comprising an effective amount
of an ECD binding agent in combination with an effective amount of one or more
chemotherapeutic agent, wherein the HPTPB-ECD binding agent and one or more
chemotherapeutic agent are administered together or in any order.
Yet another embodiment of the disclosure is a method for ng a patient diagnosed
with atic cancer, comprising administering to the patient a composition comprising an
effective amount of an HPTPB-ECD binding agent. Still another embodiment is a method for
treating a patient diagnosed with atic cancer, sing administering to the patient a
composition comprising an effective amount of an ECD binding agent in combination
with an effective amount of one or more chemotherapeutic agents, wherein the HPTPB-ECD
binding agent and one or more chemotherapeutic agents are administered together or in any
order.
Yet another embodiment of the disclosure is a method for preventing or reducing
metastasis in a patient diagnosed with pancreatic cancer, comprising administering to the patient
a composition comprising an ive amount of an HPTPB-ECD binding agent. Still another
embodiment is a method for preventing or reducing metastasis in a patient diagnosed with
pancreatic , comprising administering to the patient a ition comprising an effective
amount of an ECD binding agent in combination with an effective amount of one or
more chemotherapeutic agent, wherein the HPTPB-ECD binding agent and one or more
chemotherapeutic agents are administered together or in any order.
In some embodiments the chemotherapeutic agent used in the treatment of pancreatic
cancer is gemcitabine, or 5-flourouracil, or cisplatin or capecitabine, or oxaliplatin, or
mitomycin, or any combination thereof.
9] Still another embodiment is a method for treating a patient sed with malignant
melanoma, comprising administering to the patient a composition comprising an ive
amount of an HPTPB-ECD binding agent. Yet another embodiment is a method for treating a
patient sed with metastatic melanoma, comprising administering to the t a
composition comprising an effective amount of an HPTPB-ECD binding agent in ation
with an effective amount of one or more chemotherapeutic agent, wherein the HPTPB-ECD
binding agent and one or more chemotherapeutic agents are administered together or in any
order.
Still another ment is a method for preventing or reducing metastasis in a
patient diagnosed with malignant melanoma, comprising administering to the patient a
composition comprising an effective amount of an HPTPB-ECD g agent. Yet another
embodiment is a method for preventing or reducing metastasis in a patient diagnosed with
metastatic ma, comprising stering to the patient a composition comprising an
effective amount of an HPTPB-ECD binding agent in combination with an effective amount of
one or more herapeutic agent, wherein the HPTPB-ECD binding agent and one or more
chemotherapeutic agents are administered together or in any order.
In some embodiments the chemotherapeutic agent is used to treat melanoma is
cisplatin, or vinblastine, or dacarbazine, or any combination thereof.
Still another embodiment is a method for treating a patient diagnosed with breast
cancer comprising administering to the t a composition comprising an effective amount of
an HPTPB-ECD binding agent. Yet another embodiment is a method for treating a patient
diagnosed with breast cancer comprising administering to the patient a composition sing
an effective amount of an HPTPB-ECD binding agent in combination with an effective amount of
one or more chemotherapeutic agent, wherein the HPTPB-ECD binding agent and one or more
herapeutic agents are stered together or in any order. Yet another embodiment is a
method for preventing or reducing metastasis in a patient diagnosed with breast cancer
comprising administering to the patient a composition comprising an effective amount of an
HPTPB-ECD binding agent. Yet another embodiment is a method for preventing or reducing
metastasis in a patient diagnosed with breast cancer comprising administering to the patient a
ition comprising an effective amount of an HPTPB-ECD binding agent in combination
with an effective amount of one or more chemotherapeutic agent, n the HPTPB-ECD
binding agent and one or more chemotherapeutic agent are administered together or in any order.
In some ments the herapeutic agent is used in the treatment of breast cancer is
taxol or an analog of taxol.
In ular embodiments the ECD binding agent is administered in
ation with IL—2.
IL-2 d Vascular Leak: Treatment of Metastatic Cancers
Immunotherapy is one method of treating cancer. Up-regulation of the body’s own
immune system is one aspect of immunotherapy. Among the many immune system signaling
molecules is interleukin-2 (IL-2) which is instrumental in the body’s natural response to
microbial infection and in discriminating between foreign (non-self) and self. High-dose
interleukin-2 is an FDA approved ent for patients with metastatic renal cell carcinoma and
metastatic melanoma. Although it has been reported that only 23% of those subjects given this
y show a tumor response, the duration of this response can exceed 10 years (Elias L. et al.,
“A literature analysis of prognostic factors for response and quality of response of patients with
renal cell carcinoma to interleukinbased therapy.” Oncology, (2001), Vol. 61, pp. 91-101). As
such, IL-2 therapy is the only ble treatment that offers the potential for cure.
Gallagher (Gallagher, D.C. et al., poietin 2 Is a Potential Mediator of High-
Dose Interleukin 2-Induced Vascular Lea ” Clin. Cancer Res., (2007), Vol. 13, No. 7,
pp. 2115-
2120) reports that elevated levels of angiopoietin-2 are found in patients treated with high doses
of IL-2 and suggests that overcoming Ang-2 blockade of Tie-2 signaling might be curative for
vascular leak syndrome which is a side effect of this therapy.
IL-2 is known to cause endothelial cell activation, however, with loss of proper
barrier function. Amplification of Tie-2 signaling during high dose IL-2 therapy would
lead to ation of vascular leakage since Tie-2 stimulation promotes endothelial cell stability.
As such, by administering an agent that can amplify Tie-2 signaling, vascular ity can be
increased and, hence, the side s of high IL-2 dosing mitigated. The disclosed HPTPB-ECD
binding agents can amplify Tie-2 signaling under the conditions of low angiopoietin-l
concentrations or when high concentrations of angiopoietin-2 are present as in IL—2 treated
patients.
By ying Tie-2 signaling without affecting Ang-2 , the use of elevated
levels of Ang-2 as a potential pathology marker is ed. For example, a t suffering
from an inflammatory disease such as sepsis will normally have an elevated Ang-2 level that acts
to suppress Ang-l stimulation of Tie-2. This elevated Ang-2 s in edema which is a
symptom of vascular leakage. The present methods, by amplifying Tie-2 signaling without
affecting the Ang-2 level, e a method for alleviating the symptoms that are associated with
vascular leak while retaining the ability to use Ang-2 levels as a measure of disease progress and
resolution.
As many as 65% of patients receiving this IL-2 therapy will necessarily interrupt or
discontinue treatment due to VLS. The major dose-limiting toxicity of interleukin-2 (IL-2) and
of immunotoxin (IT) therapies is vascular leak syndrome (VLS). VLS is characterized by an
increase in vascular permeability accompanied by extravasation of fluids and proteins resulting in
interstitial edema and organ failure. Manifestations of VLS include fluid retention, hypotension,
se in body weight, peripheral edema, pulmonary edema, l and pericardial effusions,
ascites, anasarca and, in severe form, signs of pulmonary and cardiovascular failure.
The disclosed HPTPB-ECD binding agents can be used as an effective therapy to
reduce vascular leak caused by treatment with IL-2. Therefore an embodiment of the present
invention is a method of ng, reducing or preventing vascular leak in a patient being
administered IL-2 wherein the method comprises stering to the patient a composition
comprising an effective amount of an HPTPB-ECD binding agent. The HPTPB-ECD binding
agent can be co-administered with IL-2 or administered separately. The IL-2 and the HPTPB-
ECD binding agent may be stered in any order and by any method, for example,
intravenously, orally, by patch, subcutaneous injection and the like.
0] One embodiment of the t disclosure is a method for treating renal cell
carcinoma comprising administering to a t a composition comprising: a) an effective
amount of interleukin-2 such that an immune response is provided; and b) an effective amount of
an HPTPB-ECD binding agent; wherein the interleukin-2 and the HPTPB-ECD binding agent can
be administered together or in any order. Another ment disclosed herein is a method for
treating renal cell carcinoma comprising administering to a patient a composition sing: a)
a high dose of interleukin-2; and b) an effective amount of an HPTPB-ECD g agent.
Further sed is a method for treating metastatic melanoma comprising
administering to a patient a series of itions, wherein the compositions can be administered
in any order and at any effective amount, a first composition comprising, a high dose of
interleukin-2 and the second composition comprising an effective amount of an HPTPB-ECD
binding agent.
Still r disclosed is a method for treating renal cell carcinoma comprising
administering to a patient a series of compositions, wherein the compositions can be administered
in any order and at any effective amount, a first composition comprising a high dose of
interleukin-2 and the second composition comprising an ive amount of an HPTPB-ECD
binding agent.
Disclosed herein is a method for treating metastatic melanoma by administering to a
t in need of ent a therapy that comprises: a) an effective amount of interleukin-2
such that an immune response is provided; and b) an effective amount of an HPTPB-ECD
g agent; n the interleukin-2 and the HPTPB-ECD binding agent can be administered
together or in any order.
Also disclosed herein is a method for treating metastatic melanoma by administering
to a patient in need of treatment a therapy that comprises: a) an effective amount of interleukin-2
such that an immune response is provided; and b) an effective amount of an HPTPB-ECD
binding agent; n the interleukin-2 and the ECD binding agent can be administered
together or in any order.
Disclosed herein are compositions which can be used to treat patients with cancer,
wherein the patient having cancer is treated with one or more cancer agents that induce vascular
leak syndrome in the patient. As such, disclosed herein are compositions effective in reducing
vascular leak resulting from a cancer treatment, the compositions comprising an effective amount
of an HPTPB-ECD binding agent.
Another aspect sed herein are compositions ive for treating humans or
other mammals having a medical condition or disease state wherein the treatment for the medical
condition or disease state induces vascular leak syndrome, the composition comprising: a) an
effective amount of an HPTPB-ECD binding agent; and b) one or more pharmaceutical drugs;
wherein at least one of the pharmaceutical drugs induces vascular leak syndrome.
7] In a further aspect, disclosed herein are itions comprising: a) an effective
amount of an HPTPB-ECD binding agent; and b) one or more chemotherapeutic agent.
Also disclosed herein are compositions which can be used to control ar leakage,
the itions comprising an effective amount of one or more of the agents disclosed herein.
Still further disclosed herein are compositions which can be used to treat patients with an
inflammatory e, non-limiting examples of which include sepsis, lupus, and inflammatory
bowel disease, the compositions comprising an ive amount of an HPTPB-ECD binding
agents disclosed herein. The HPTPB-ECD binding agents inhibit the Tie2 dephosphorylase
activity of HPTPB acting as Tie-2 ing amplifiers.
9] Tumor growth is often a multi-step process that starts with the loss of control of cell
proliferation. The cancerous cell then begins to divide rapidly, resulting in a microscopically
small, id tumor: an in situ carcinoma. As the tumor mass grows, the cells will find
themselves further and further away from the nearest capillary. Finally the tumor stops growing
and reaches a steady state, in which the number of proliferating cells counterbalances the number
of dying cells. The restriction in size is caused by the lack of nutrients and oxygen. In tissues, the
oxygen diffusion limit corresponds to a distance of 100 um between the capillary and the cells,
which is in the range of 3-5 lines of cells around a single vessel. In situ carcinomas may remain
dormant and undetected for many years and metastasis are rarely associated with these small (2
to 3 mmz), avascular tumors.
When a tumor’s growth is stopped due to a lack of nutrients and/or , this
reduction in tumor vasculature also limits the ability of anti-tumor drugs to be delivered to the
malignant cells. Moreover, if there is a slight increase in tumor vasculature, this will allow
delivery of anti-tumor therapies to the ant cells without initiating metastasis. As such, the
disclosed agents when used to slightly amplify Tie-2 signaling can be used to increase blood flow
to the tumor cells without setting off asis or uncontrolled tumor cell proliferation while
providing a method for delivering anti-cancer drugs to malignant cells.
WO 56240
sed herein, is a method for ng cancer comprising administering to a patient
in need an effective amount of an HPTPB-ECD binding agent in conjunction with one or more
chemotherapeutic compound or immunotherapeutic compound. To “slightly amplify Tie-2
signaling” means that a ient amount of a disclosed compound is administered to a patient
such that the amount of tumor cell vasculature is increased such that the increased circulation
allows for delivery of the anti-tumor compound or therapy without instigating tumor growth
wherein the rate of tumor cell growth is less than the rate of tumor cell death. It is recognized
that amplifying Tie2 signaling would stabilize the tumor vasculature making it ant to
angiogenic signals reducing tumor angiogenesis and tumor growth while improving tumor blood
flow and the delivery of chemotherapeutic agents.
Angiopoietin-2 is significantly correlated to Gleason Score, metastasis and to cancer
specific survival (Lind A.J. et al., “Angiopoietin-2 expression is related to histological grade,
ar density, metastasis and outcome in prostate cancer” Prostate, (2005), Vol. 62, pp. 394-
299). Angiopoietin-2 was found to be expressed in prostate cancer bone, liver and lymph node
metastasis, but with little to no oietin-l expression in prostate cancer tumor cells in bone,
liver and lymph nodes ssey C. et al., rential expression of angiogenesis associated
genes in prostate cancer bone, live and lymph node metastasis” Clin. Exp. Metastasis, (2008),
Vol. 25, pp. 377-388). As such, monitoring the level of Ang-2 provides a method for ting
the presence of prostate cancer and the spread of prostate cancer cells throughout the body due to
vascular leakage.
Thus, another ment of the disclosure is a method of evaluating efficacy of
treatment sing monitoring the Ang-2 level of the patient while the patient is undergoing
treatment.
Vasculature Stabilization in Diseases Caused by Pathogens
Disclosed herein is a method for preventing or treating vascular leak me caused
by one or more pathogens, comprising administering to a human or other mammal in need of
treatment an effective amount of one or more HPTPB-ECD binding agent.
One embodiment is a method for treating ar leak syndrome caused by one or
more pathogens, comprising administering to a human or other mammal in need of treatment a
composition comprising: a) an effective amount of one or more compounds effective against a
pathogen present in the human or mammal; and b) an ive amount of an HPTPB-ECD
binding agent; n the one or more compounds effective against a pathogen and the HPTPB-
ECD binding agent can be stered together or in any order.
Further disclosed is a method for ting ar leak syndrome in a human or
other mammal diagnosed with a pathogen infection that can produce vascular leak syndrome in a
human or , comprising administering to a human or mammal a composition comprising:
a) an effective amount of one or more compounds effective against a pathogen present in the
human or mammal; and b) an effective amount of one or more HPTPB-ECD binding agent;
wherein the one or more compounds effective against a pathogen and the one or more HPTPB-
ECD g agent can be administered together or in any order.
The following are non-limiting examples of viruses, bacteria and other pathogens
where virulence can be controlled by ting the degree of vascular leak that is induced by the
sm. Staphylococcus aureus, Bacillus anthracis, Pseudomonas, Streptococcus pyogenes,
and dengue virus.
One embodiment is a method for treating vascular leak me in a patient
suffering from a bacterial infection by administering to the patient a ition comprising an
effective amount of an HPTPB-ECD binding agent. Further disclosed is a method for preventing
vascular leak syndrome in a human or other mammal diagnosed with a bacterial infection.
Thus one embodiment of the present disclosure is a method of treating a patient
suffering from a bacterial infection by administering to the patient a composition comprising an
effective amount of an HPTPB-ECD binding agent. In particular embodiments the ial
infection is a Bacillus anthracis infection. In other embodiments the bacterial infection is a
Pseudomonas infection. In yet other embodiments the bacterial ion is a Streptococcus
es infection.
One embodiment is a method for treating vascular leak syndrome in a patient
ing from a viral infection by administering to the patient a composition comprising an
effective amount of an HPTPB-ECD binding agent. Further disclosed is a method for preventing
vascular leak syndrome in a human or other mammal diagnosed with a viral infection.
2012/060273
Another ment is a method of treating a patient suffering from a viral infection
by administering to the patient a composition comprising an effective amount of an HPTPB-ECD
binding agent. In particular embodiments the viral infection is a dengue virus infection.
The HPTPB-ECD binding agent may be administered in combination with one or
more cterial or antiviral agent wherein the HPTPB-ECD binding agent and the ral or
antibacterial agents can be administered together or in any order. Thus, an embodiment of the
present disclosure is a method of treating a patient suffering from a bacterial infection comprising
administering: a) an ECD binding agent; and b) one or more antibacterial agents, wherein
the HPTPB-ECD binding agent and antibacterial agent can be administered together or in any
order. Another embodiment of the present disclosure is a method of treating a patient suffering
from a viral infection comprising administering: a) an HPTPB-ECD binding agent; and b) one or
more ral agents wherein the HPTPB-ECD binding agent and antiviral agent can be
administered together or in any order.
Another method provided by the present disclosure, is a method for determining the
course of treatment for a patient suffering from vascular leak me, comprising:
a) administering to a patient a composition comprising an effective amount of an HPTPB-ECD
binding agent; b) monitoring the level of angiopoietin-2 present in the patient during the course
of treatment; and c) tinuing treatment when the angiopoietin-2 level returns to within a
normal range.
A further aspect relates to s of treating vascular leak in a patient infected with
anthrax comprising administering a composition comprising an effective amount of an HPTPB-
ECD g agent in combination with an effective amount of one or more antibacterial agents
effective against anthrax, wherein the HPTPB-ECD binding agent and the antibacterial agents
effective t anthrax are administered together or in any order.
Yet another aspect relates to methods of treating vascular leak in a patient infected
with a virus comprising administering a composition comprising an effective amount of an
HPTPB-ECD g agent in combination with an effective amount of one or more antiviral
, wherein the HPTPB-ECD g agent and the antiviral agent are administered together
or in any order.
Increased amplification of Tie-2 signaling using the disclosed agents provides a
method for stabilizing vasculature t the need to affect Ang-l and/or Ang-2 levels.
Disclosed herein are methods for stabilizing vasculature, comprising administering to a patient an
effective amount of an HPTPB-ECD binding agents.
e the disclosed agents can amplify Tie-2 signaling without increasing the
amount of Ang-2, monitoring the amount of Ang-2 in blood serum of a patient while
administering to a patient an HPTPB-ECD binding agent, serves as a method for determining the
course of various illnesses or disease states associated with vascular leak syndrome, for example,
sepsis as a result of infection. As such, disclosed is a method for stabilizing vasculature in a
patient suffering from an atory disease wherein the level of oietin-2 is elevated,
comprising: a) administering to a patient an ive amount of an HPTPB-ECD binding agent;
b) monitoring the level of angiopoietin-2 present in the patient; and c) discontinuing treatment
when the angiopoietin-2 level returns to a normal range.
What is meant herein by “normal angiopoietin-2 level” is an amount of Ang-2 in
blood serum of from about 1 ng/mL to about 2 ng/mL. Alternatively, the level of Ang-2 can be
determined for an individual suffering from a disease state, for example, severe sepsis and the
level of Ang-2 can be monitored until the amount of Ang-2 in the patient’s serum drop to a level
that is nearer the normal range. In this case, the co-administration of a drug can be continued or
discontinued.
Therefore, disclosed herein is a method for stabilizing the vasculature of a t
during a course of treatment, comprising: a) co-administering to a patient an effective amount of
an HPTPB-ECD binding agent and one or more drugs as a treatment; b) ring the level of
angiopoietin-2 present in the patient; and c) discontinuing the administration of the one or more
drugs, and selecting one or more other drugs for use as a treatment if the level of serum
oetin-2 does not decrease.
The HPTPB-ECD g agent, while stabilizing the vasculature of a patient such
that a course of treatment against a pathogen can be sustained, can also be used to stabilize a
patient during a period wherein an effective treatment t a pathogen is being determined.
That is, the HPTPB-ECD binding agents by themselves can have a beneficial effect on the
outcome of es caused by pathogens by ng vascular leak and its complications.
Any of the foregoing compositions comprising an HPTPB-ECD binding agent are
suitable for use in the manufacture of a medicament for treatment of any of the diseases or
disorder described above. In addition, any of the foregoing compositions comprising an HPTPB-
ECD binding agent are le for use in treating any of the diseases or disorder bed
above.
In Vivo Vascular Leak
The Miles assay (Miles, A. A. and E. M. Miles (1952) Vascular reactions to
histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs. J. Physiol., Vol. 118,
pp. 228-257 incorporated herein by reference in its entirety) can be used to directly investigate
and fy lethal toxin, as well as edema toxin (ET [PA plus ediated vascular leakage in
the mouse model. The following is a modified Miles assay as described by Gozes Y. et al.,
Anthrax Lethal Toxin Induces Ketotifen-Sensitive Intradermal Vascular Leakage in Certain
Inbred Mice Infect. Immun., 2006 February, Vol. 74, No. 2, pp. 1266—1272 incorporated herein
by reference in its entirety, that can be used to evaluate the disclosed HPTPB-ECD binding agents
for their ability to prevent ar leakage in humans and animals exposed to x.
Highly pure PA, LF, and mutant LF E687C are purified as previously described
(Varughese M. et al., (1998) Intemalization of a Bacillus anthracis tive antigen-c-Myc
fusion protein mediated by cell surface anti-c-Myc antibodies. Mol. Med. 4:87-95 included
herein by reference in its entirety). Doses of ET or LT refer to the amount of each component
(i.e., 100 ug LT is 100 ug PA plus 100 ug of LP). All drugs except for azelastine can be
sed from Sigma Aldrich (St. Louis, MO); azelastine can be purchased from LKT
Laboratories (St. Paul, MN). LT is an abbreviation for lethal toxin; PA is an abbreviation for
protective n; LP is an abbreviation for lethal factor; and EP is an iation for edema
factor.
BALB/cJ, DBA/2J, J, C3H/HeOuJ, WBB6F1/J-KitW/KitW'V, and colony-
matched wild-type homozygous l mice can be purchased from The Jackson Laboratory
(Bar Harbor, ME). BALB/c nude, C57BL/6J nude, and C3H hairless (C3.Cg/TifBomTac-hr) mice
can be purchased from Taconic Farms (Germantown, NY). C3H nude mice can be purchased
from The National Cancer Institute Animal Production Area (Frederick, MD). Mice are used
when they are 8 to 12 weeks old. Except for C3H hairless and nude animals, all mice are shaved
24 hours prior to intradermal (i.d.) injections. In order to assess the susceptibility to systemic LT,
mice are injected intraperitoneally (i.p.) with 100 pg LT and observed over 5 days for signs of
malaise or death. Fischer 344 rats can be purchased from Taconic Farms (Germantown, NY) and
used at weights of 150 to 180 g. Rats are injected intravenously (iv) in the tail vein with 12 pg
LT, with or without 250 pg of the mast cell stabilizer drug ketotifen and monitored for the exact
time to death.
Miles Assay.
The Miles assay uses iv. injection of Evans blue dye (which binds to endogenous
serum albumin) as a tracer to assay olecular leakage from peripheral vessels after i.d.
injection of test substances. Nude mice and normal shaved mice are injected iv. with 200 pl of
0.1% Evans blue dye (Sigma al Co., St. Louis, MO). After 10 min, 30 pl of test toxin or
control samples (PA only, LF only, EF only, or phosphate-buffered saline) are injected id. in
both left and right flanks, as well as at single or dual dorsal sites. To quantify the extents of
leakage, equally sized (1.0- to 1.5-cm er) skin regions surrounding i.d. injection sites are
removed 60 min after injection and placed in formamide (1 ml) at 410C for 48 h, allowing for
dye extraction. The A620 of samples is read, and the extent of leakage is calculated by
comparison with phosphate-buffered -, PA-, or LF-treated controls.
In experiments wherein the effectiveness of the HPTPB-ECD binding agents are
tested for LT-mediated e, mice are injected iv. with Evans blue as described above, and
the test agent introduced ically through i.p. ion 10 min after dye injection. LT was
introduced by i.d. injection 30 min after the injection of Evans blue. In another embodiment, the
agent to be tested can be introduced locally by i.d. ion and LT ed in the same site after
min.
Cytotoxicity Experiments.
MC/9 mast cells can be obtained from ATCC (Manassas, VA) and grown in
Dulbecco's modified Eagle's medium supplemented with l-glutamine (2 mM), 2-mercaptoethanol
(0.05 mM), Rat T-STIM (BD Biosciences-Discovery Labware, Bedford, MA) (10%), and fetal
bovine serum (PBS, 10% final concentration; ogen-GIBCO BRL, Gaithersburg, MD). Cells
are then seeded at a density of 104/well in 96-well plates prior to treatment with various LT
concentrations or PA-only controls. After 6, 12, and 24 hours, viability is assessed using
Promega's CellTiter 96 AQueous One Solution cell proliferation assay (Promega, Madison, WI)
2012/060273
per the manufacturer's protocol. Alternatively, toxicity assays can be performed in medium
provided with all supplements except FBS (serum-free medium). In other embodiments, pooled
human umbilical vein endothelial cells (HUVECs) at third to fifth passage can be ed from
x Corp. (Cambrex, Walkersville, MD) and grown in an EGM-MV Bulletkit (Cambrex,
Walkersville, MD) in flasks pretreated with endothelial cell ment factor (Sigma, St. Louis,
MO). For cytotoxicity experiments, cells are lly seeded in 96-well plates in an EGM-MV
Bulletkit. On the day of assays, this medium is then replaced with M199 medium (Sigma, St.
Louis, MO) supplemented with 10% PBS or human serum (Sigma, St. Louis, MO), and cells are
ed in 96-well plates at a density of 2 x 103/01 ml/well and treated with various
concentrations of LT in triplicate. Cell viability is typically assessed as for MC/9 cells at 24, 48
and 72 hour time points.
HUVEC Permeability Assay
HUVEC monolayers can be effectively cultured on Transwell-Clear cell culture
inserts (6.5-mm diameter, 0.4-um pore size; -Costar, Acton, MA) in l plates,
creating a two-chamber culturing system ting of a l compartment (inside the insert)
and a subluminal compartment (the tissue culture plate well). Prior to seeding cells, the inserts
are coated with endothelial cell attachment factor (Sigma, St. Louis, MO). Pre-warmed CS-C
medium (Sigma, St. Louis, MO) containing 10% iron-supplemented calf serum and 1%
endothelial cell growth factor (Sigma, St. Louis, MO) is added to wells prior to insert placement.
A HUVEC cell suspension (200 uL of 5 x 105 cells/ml) is then added to each insert. Cells are
cultured at 37 0C in 5% C02 for up to 21 days to ensure proper formation of a monolayer. For
testing barrier function, medium can be changed to RPMI supplemented with 10% PBS or to
RPMI without serum. To assess barrier function, horseradish peroxidase enzyme (Sigma, St.
Louis, MO) is added to the inserts (10 ug/well). LT (1 ug/mL) or control treatments of PA alone
(1 ug/mL) or LP alone (1 ug/mL) are added to duplicate wells, and every hour (for 12 hours), a
sample of 10 uL was taken from the subluminal tment and tested for the enzymatic
activity of horseradish peroxidase by adding 100 uL substrate [2’,2’-azino-bis(3-ethylbenzthizolin
6-sulfonic acid)] (A-3219; Sigma, St. Louis, MO) and reading at 405 nm.
Anthrax Combination y
Increased stabilization of vascular tissue can increase the iveness of known
antimicrobials against anthrax infection. As such, HPTPB-ECD binding agents can be evaluated
as a combination therapy for the treatment of x. The following describes a series of assays
that can be used to determine the effectiveness of an HPTPB-ECD binding agent as one part of a
combination therapy useful for treating anthrax infections.
LF has been found to cleave mitogen-activated protein kinase s ),
disrupts signal transduction, and leads to macrophage lysis. As such, in addition to the Miles
Assay, the following ased and peptide cleavage assay can be used to confirm the potency of
the HPTPB-ECD binding agents to inhibit the effect of LT ty. For the following assay,
MAPKKide can be purchased from List Biological Laboratories (Campbell, CA. Fluorinated
peptide substrate is available from Anaspec (San Jose, CA).
In Vivo Assays
One week before beginning an evaluation of a combination course of treatment for
anthrax, test agents (200 mg each) are dissolved in 800 ML of DMSO and stored at -20 0C.
Immediately before injection, each test agent is diluted in PBS, resulting in a final concentration
of 0.5 mg/mL in 2% DMSO. Test animal are nged on day 0 with 2 x 107 spores per mouse
in PBS through i.p. injection. Treatment was started 24 hours after challenge. One example of a
suitable ent regimen is the combination of ciprofloxacin (50 mg/kg) and an HPTPB-ECD
binding agent (5 mg/kg). A control sample of untreated animals, ciprofloxacin alone, a disclosed
agent alone and ciprofloxacin in combination with a disclosed agent are given to the animals and
they are monitored twice per day until day 14 after injection.
Ciprofloxacin and the agent to be tested can be conveniently stered through
parenteral ion with a volume of 200 ML for each once per day for 10 days. All surviving
animals are sacrificed on day 14. Sick animals that appear moribund (i.e., exhibiting a severely
reduced or absent activity or locomotion level, an unresponsiveness to external stimuli, or an
inability to obtain readily available food or water, along with any of the following accompanying
signs: ruffled haircoat, hunched posture, ity to in normal body temperature, signs of
hypothermia, respiratory distress, or other severely tating condition) should be sacrificed on
the same day these symptoms are manifested.
Modulation of Bacterium-Induced Vascular Leak
Pathogenic bacteria are known to cause vascular leak. This induced vascular e
inhibits the ability of antimicrobials and other pharmaceuticals from targeting the invading
microorganism. As such, HPTPB-ECD g agents can be used alone or in combination with
other pharmaceutical ingredients to boost the host immune system by preventing excess vascular
leakage that occurs as a result of a bacterial infection.
The following describe tests and assays that can be used to determine the
effectiveness of an HPTPB-ECD binding agent, either alone, or a combination therapy.
Staphylococcus aureus (S. aureus) is a major pathogen of gram-positive septic shock
and is associated with consumption of plasma kininogen. The effect of an HPTPB-ECD binding
agent on S. aureus induced vascular leakage activity can be determined by measuring the activity
of these agents with respect to two cysteine nases that are ed by S. .
Proteolytically active staphopain A (ScpA) s vascular leakage in a bradykinin (BK) B2-
receptor—dependent manner in guinea pig skin. This effect is augmented by staphopain B (SspB),
which, by itself, had no vascular leakage activity. ScpA also produces vascular leakage activity
from human plasma.
An important pathophysiologic mechanism of septic shock is hypovolemic
hypotension that is caused by plasma leakage into the extravascular space. It has been found that
ScpA d vascular leakage at a concentration as low as 20 nM within 5 minute after injection
into the guinea pig skin—with the reaction being augmented by coexisting SspB indicating that
vascular leakage induction by these proteinases occurs efficiently in vivo (Imamura T. et al.,
Induction of vascular leakage through release of bradykinin and a novel kinin by cysteine
proteinases from Staphylococcus aureus (2005) J. mental ne, Vol. 201, No. 10, pp.
1669-1676).
Vascular Leakage Assay.
Animals can be evaluated for vascular leakage using the following procedure. 100 ML
of a 1% solution of Evans blue dye (Sigma Aldrich) in saline is injected into the tail vein. Thirty
minutes later, mice are sacrificed and perfused with saline via the right ventricle to remove
ascular Evans blue. Lungs are excised and extracted in 1 mL of formamide at 55 0C
overnight. Evans blue content is determined as OD620 minus OD500 of the formamide extract.
The agents disclosed herein can be used as a single ceutical therapy to reduce
the ty of influenza by ing the effects of vascular leak caused by viruses, and, hence,
allowing the body’s own immune system to affect greater resistance to these pathogens. The
following assays can be used to determine the effect of an HPTPB-ECD binding agent to inhibit
viral ty because of improved ar integrity.
The disclosed assays can use inhibition of viral plaques, viral thic effect (CPE),
and viral hemagglutitin.
Proteolytic Sensitivity Assay
An HPTPB-ECD binding agent can be determined to bind to hemagglutinin and
thereby destabilize the protein assembly. The following ure can be used to determine the
se in destabilization and ore the increased sensitivity of hemagglutinin to lytic
attack caused by an HPTPB-ECD binding agent. At the fusion conformation, HA becomes more
sensitive to protease digestion. This property can be used to verify if a fusion inhibitor interacts
with HA (Luo G. et al., “Molecular mechanism underlying the action of a novel fusion inhibitor
of influenza A ” J. Virol., (1997), Vol. 71, No. 5, pp. 4062-4070). Thus, an HPTPB-ECD
binding agent, due to the control of vascular leakage, can be evaluated for its ability to indirectly
effect HA ion by enhancing the body’s immune response.
The purified trimer of hemagglutinin ectodomain is incubated with the agent to be
tested at a tration of 5 MM. The trimers are subjected to trypsin digestion at pH 7.0 and
pH 5.0 with controls of untreated HA and HA treated with DMSO which is the solvent used to
dissolve the test agent. For the pH 5.0 sample, the HA trimers are treated with a pH 5.0 buffer
for 15 minutes and neutralized to pH 7.0. Trypsin (20 ng) is added to the sample in 10 ML and
the digestion d to proceed for 1 hour at 37 0C, The amount of HA t is assessed by a
western blot gel electrophoresis using anti-HA (H3) antisera. Samples containing effective
tors will provide an increase in digestion of HA by trypsin.
In addition, combination therapies can provide a method for treating influenza by
providing an antiviral medication together with an agent that prevents the severity of vascular
leakage due to influenza viruses.
An antiviral compound, for example, oseltamivir, can be used for an in vivo
evaluation of the disclosed combination therapy and to evaluate the effectiveness of an HPTPB-
ECD binding agent. The drug combination is administered in a single dose to mice infected with
the influenza A/NWS/ (HlNl) virus. In some ces, infection of the animals will include
multiple passage of the virus through their lungs. One convenient protocol involves
administering 20 mg/kg per day twice daily for 5 days beginning 4 hours prior to virus exposure.
The animals are then challenged with different concentrations of virus, ranging 10-fold from 10'2
(105'75 cell culture 50 % infectious doses 0) per mL). Four mice in each group are
iced on day 6 and their lungs removed, assigned a consolidation score ranging from 0
(normal) to 4 (maximal plum coloration), weighted, nized, the homogenates fuged
at 2000 x g for 10 minutes, and varying 10-fold dilutions of the supernatant assayed for virus titer
in MDCK cells using CPE produced after a r incubation at 37 0C as endpoint.
The serum taken from mice on day 6 is assayed for a1-AG using single radial
diffusion kites. Eight additional mice in each group are continually observed daily for
death for 21 days, and their arterial oxygen saturation (SaOz) values determined by pulse
oximetery (Sidwell R. et al., (1992) Utilization of pulse oximetry for the study of the inhibitory
effects of antiviral agents on influenza virus in mice. Antimicrob. Agents Chemother. 36, 473-
476) on day 3, when SaOz decline usually begins to occur, through day 11, when the values are
seen to decline to the maximum degree of the animals otherwise die.
Inhibition of Protein Tyrosine atase beta in a Cell
Disclosed herein are methods for inhibiting protein tyrosine phosphatase beta (HPTP-
B) activity in a cell, comprising contacting a cell with an effective amount of an HPTPB-ECD
binding agents. The cell can be contacted in vivo, ex vivo, or in vitro.
Administration
Depending on the nature of the ular agent, agents of the present disclosure can
be administered to humans and other animal, parenterally, (e. g., by intravenous or intraperitoneal
ion), subcutaneously, orally, topically, rectally, buccally, as an oral or nasal spray.
The HPTPB-ECD binding agents of the disclosure are preferably formulated in dosage
unit form for ease of administration and uniformity of . The expression “dose” or “dosage
unit form” as used herein refers to a physically discrete unit of agent appropriate for the patient to
be treated. It will be understood, however, that the total daily usage of the HPTPB-ECD binding
agents and compositions of the present invention will be decided by the attending physician
within the scope of sound medical judgment.
Dosing
Effective dosages and schedules for administering the HPTPB-ECD binding agent
may be determined cally, and making such determinations is within the skill in the art.
Those skilled in the art will understand that the dosage of the agent that must be administered
will vary depending on, for example, the t which will receive the agent, the route of
administration, the particular type of agent used and other drugs being stered to the
subject. For example, guidance in selecting appropriate doses for antibodies is found in the
literature on therapeutic uses of antibodies, e. g., Handbook of Monoclonal Antibodies, Ferrone et
al., eds., Noges Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al.,
Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977)
pp. 365-389. A typical dose of the agent used alone might range from about 0.01 mg/kg to up to
500 mg/kg of body weight or more per day, or from about 0.01 mg/kg to about 50 mg/kg, or from
0.1 mg/kg to about 50 mg/kg, or from about 0.1 mg/kg to up to about 10 mg/kg, or from about
0.2 mg/kg to about 1 mg/kg, or from about lmg/kg to about depending on the factors mentioned
above.
The dosing schedules for administration of an HPTPB-ECD binding agent include, but
are not limited to, once daily, three-times weekly, twice weekly, once weekly, three times, twice
monthly, once monthly and once every other month.
Formulations
In one aspect of the t invention, pharmaceutically able compositions are
provided, wherein these compositions se any of the agents as described , and a
pharmaceutically acceptable carrier and, in addition, can include other pharmaceutical agents,
adjuvants or diluents. For e, ceutical compositions can also include one or more
onal active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics
and the like.
The formulation may vary depending on the mode of administration. The
pharmaceutical compositions can be in the form of solid, semi-solid or liquid dosage forms, such
as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions,
creams, gels, or the like, preferably in unit dosage form suitable for single administration of a
precise dosage.
For the purposes of the present disclosure the term “excipient” and “carrier” are used
interchangeably hout the description of the t disclosure and said terms are defined
herein as, “ingredients which are used in the practice of formulating a safe and effective
pharmaceutical composition.’ 7 The formulator will understand that excipients are used primarily
to serve in ring a safe, stable and functional pharmaceutical, serving not only as part of the
overall vehicle for delivery but also as a means for achieving effective absorption by the recipient
of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler,
or an excipient as used herein may be part of a pH izing system or coating to insure delivery
of the ingredients.
“Pharmaceutically acceptable” means a material that is not biologically or otherwise
undesirable, i.e., the material may be administered to a patient t causing any undesirable
biological effects or interacting in a deleterious manner with any of the other components of the
pharmaceutical formulation in which it is contained. The carrier would naturally be selected to
minimize any degradation of the active ingredient and to minimize any adverse side s in the
patient, as would be well known to one of skill in the art. See Remington's Pharmaceutical
Sciences, 18th ed., Gennaro, AR. Ed., Mack Publishing, Easton Pa. (1990), which discloses
typical carriers and conventional methods of preparing ceutical compositions that can be
used in conjunction with the preparation of formulations of the agents described herein. It will
be apparent to those s skilled in the art that n carriers can be more preferable
depending upon, for ce, the route of administration and concentration of composition being
administered.
For solid compositions, conventional nontoxic solid carriers include, for example,
pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc,
cellulose, glucose, sucrose, magnesium ate and the like. Liquid pharmaceutically
administrable compositions can, for example, be prepared by ving, dispersing, etc., an
active agent as described herein and optional pharmaceutical nts in an excipient, such as,
for example, water, saline aqueous dextrose, glycerol, ethanol and the like, to thereby form a
solution or suspension. If desired, the pharmaceutical composition to be administered can also
contain minor amounts of nontoxic auxiliary nces such as wetting or emulsifying agents,
pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate,
triethanolamine sodium acetate, anolamine oleate, etc. Actual methods of ing such
dosage forms are known, or will be apparent, to those skilled in this art.
The disclosed agents can also be present in liquids, emulsions, or suspensions for
delivery of active therapeutic agents. Liquid pharmaceutically administrable compositions can,
for example, be prepared by dissolving, dispersing, etc., an active agent as described herein and
optional pharmaceutical nts in an ent, such as, for example, water, saline aqueous
dextrose, glycerol, ethanol and the like, to y form a solution or suspension. If desired, the
pharmaceutical composition to be administered can also contain minor amounts of nontoxic
auxiliary substances such as wetting or emulsifying , pH buffering agents and the like, for
example, sodium acetate, sorbitan monolaurate, triethanolamine sodium e, triethanolamine
oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to
those skilled in this art; for example see Remington's Pharmaceutical Sciences, 18th ed.,
Gennaro, AR. Ed., Mack Publishing, Easton Pa. (1990).
able preparations, for example, sterile inj ectable aqueous or nous
suspensions may be formulated according to the known art using le dispersing or wetting
agents and suspending agents. The sterile injectable preparation may also be a sterile injectable
solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for
e, as a solution in l,3-butanediol. Among the acceptable vehicles and solvents that may
be employed are water, ’s solution, U.S.P. and isotonic sodium chloride on. In
addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For
this e any bland fixed oil can be employed including synthetic mono- or diglycerides. In
addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable ations can be sterilized, for example, by filtration through a
bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water or other sterile injectable
medium prior to use.
The disclosed agents can also be present in liquids, ons, or suspensions for
delivery of active therapeutic agents in aerosol form to cavities of the body such as the nose,
throat, or bronchial passages. The ratio of agents to the other compounding agents in these
preparations will vary as the dosage form requires.
Depending on the intended mode of administration, the pharmaceutical compositions
can be in the form of solid, semi-solid or liquid dosage forms, such as, for e, tablets,
suppositories, pills, capsules, powders, liquids, suspensions, s, creams, gels, or the like,
preferably in unit dosage form suitable for single administration of a precise . The
compositions will include, as noted above, an effective amount of the agents in combination with
a pharmaceutically acceptable carrier and, in addition, can include other medicinal agents,
pharmaceutical agents, carriers, adjuvants, diluents, etc.
When the agents are to be delivered into a mammal other than a human, the mammal
can be a non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent.
The terms human and mammal do not denote a particular age or sex. Thus, adult and newborn
subjects, as well as fetuses, r male or female, are ed to be covered. A patient,
subject, human or mammal refers to a subject afflicted with a disease or disorder. The term
“patient” includes human and nary subjects.
KITS
Also disclosed are kits comprising the agents be delivered into a human, mammal, or
cell. The kits can comprise one or more packaged unit doses of a composition comprising an
HPTPB-ECD binding agent to be delivered into a human, mammal, or cell. The kit optionally
includes directions for using the components of the kit. The agents can be packaged as a sterile
ation, and the ically sealed container is designed to preserve sterility of the
formulation until use.
EXAMPLES
EXAMPLE 1
Production of the HPTPB Extracellular Domain Protein
Full length HPTPB cDNA (SEQ ID NO: 1) is cloned from a human placental library
ing to the cturer's (Origene) instructions. A cDNA ng the entire soluble
extracellular domain (ECD) of HPTPB is cloned by PCR from the full length cDNA coding for
amino acids 1-1621 with an added c-terminal His-His-His-His-His-His-Gly (6His-Gly) (SEQ ID
N03). The resulting cDNA is cloned into mammalian expression vectors for transient (pShuttle-
CMV) or stable (pcDNA3.l(-)) expression in HEK293 cells. To obtain purified HPTPB ECD
(BED), HEK293 cells transfected with a BECD expression vector are incubated in OptiMEM-
serum free (Gibco) for 24 hours under normal growth conditions. The conditioned media is then
recovered, centrifuged to remove debris, and 1 mL of washed Ni-NTA e (Qiagen) (500 uL
packed al) is added to each lOuL of cleared media and allowed to rock overnight at 40 C.
2012/060273
On the following day, the mixture is loaded into a column and washed with 20 bed volumes of
50 mM NaHzPO4, 300 mM NaCl, 20 mM imidazole, pH 8. The purified HPTPB extracellular
domain protein (SEQ ID NO:4) is then eluted with 200 uL/elution in 50 mM NaHzPO4, 300 mM
NaCl, 250 mM Imidazole, pH 8. Fractions are analyzed for protein content using reducing-
denaturing lyacrylimide gel electrophoresis and detected by silver stain (Invitrogen) and
confirmed by mass spectrometry.
EXAMPLE 2
Purified HPTPB extracellular domain protein is produced, for example by the
procedure described in Example 1. For production of the HPTPB extracellular domain
immunogen, the purified HPTPB extracellular domainHis protein is conjugated to porcine
thyroglobulin (Sigma) using EDC coupling try (Hockfield, S. et al., (1993) Cold Spring
Habor Laboratory Press., Vol. 1 pp. 111-201, cytochemistry). The resulting HPTPB
extracellular domain-thyroglobulin conjugate is dialyzed against PBS, pH 7.4. Adult Balb/c
mice are then immunized subcutaneously with the conjugate (100-200 Mg) and complete Freund's
adjuvant in a 1:1 mixture. After 2-3 weeks, the mice are injected intraperitoneally or
subcutaneously with incomplete Freund's adjuvant and the conjugate in a 1:1 mixture. The
injection is repeated at 4-6 weeks. Sera are collected from mice 7 days hird-injection and
assayed for immunoreactivity to HPTPB extracellular domain antigen by ELISA and western
blotting. Mice that display a good response to the antigen are boosted by a single intra-spleen
injection with 50 ul of purified HPTPB extracellular domain protein mixed 1:1 with Alum
hydroxide using a 31 gauge extra long needle (Goding, J. W., (1996) Monoclonal dies:
Principles and Practices. Third n, Academic Press Limited. . Briefly, mice are
anesthetized with 2.5% avertin, and a 1 centimeter incision is created on the skin and left oblique
body wall. The antigen mixture is administered by inserting the needle from the ior portion
to the anterior portion of the spleen in a longitudinal injection. The body wall is d and the
skin is sealed with two small metal clips. Mice are red for safe recovery. Four days after
surgery the mouse spleen is d and single cell suspensions are made for fusion with mouse
myeloma cells for the creation of hybridoma cell lines (Spitz, M., (1986) Methods In
Enzymology, Vol. 121. Eds. John J, Lagone and Helen Van Vunakis. pp. 33-41 (Academic Press,
New York, NY)). Resulting hybridomas are ed in Dulbeccos modified media (Gibco)
supplemented with 15 % fetal calf serum (Hyclone) and hypoxathine, terin and
thymidine.
Screening for positive hybridomas begins 8 days after the fusion and continues
for 15 days. Hybridomas producing anti-ΗΡΤΡβ extracellular domain antibodies are
identified by ELISA on two sets of 96-well plates: one coated with the histidine tagged-
ΗΡΤΡβ extracellular domain and another one coated with a histidine-tagged bacterial MurA
protein as a negative control. The secondary antibody is a donkey anti-mouse IgG labeled
with horseradish peroxidase (HRP) (Jackson Immunoresearch). Immunoreactivity is
monitored in wells using color development ted by ABTS tablets dissolved in TBS
buffer, pH 7.5. The individual HRP reaction mixtures are terminated by adding 100
microliters of 1% SDS and reading absorbance at 405 nm with a spectrophotometer.
Hybridomas producing antibodies that interact with ΗΡΤΡβ extracellular domain-6His, and
not with the His n are used for further analysis. Limiting dilutions (0.8 cells per
well) are med twice on positive clones in 96 well plates, with clonality defined as
having greater than 99% of the wells with positive reactivity. Isotypes of antibodies are
ined using the iso-strip technology ). To obtain purified antibody for further
evaluation, tissue culture supernatants are affinity purified using a protein A or a protein G
column.
] Six monoclonal antibodies immunoreactive to ECD protein were
ed and given the following nomenclature, R15E6, R12A7, R3A2, R11C3, R15G2 and
R5A8. Based on its reaction with ΗΡΤΡβ-ΕCD protein in ELISA and in western blots, R15E6
was selected for further study.
EXAMPLE 3
The onal antibody R15E6
The monoclonal antibody R15E6 was identified and characterized as
described in Example 2 of the present application and in U.S. Pat. No. 7,973,142; the
procedure and results are summarized below.
A. R15E6 binds endogenous ΗΡΤΡβ as demonstrated by immunoprecipitation.
Materials: Human umbilical vein endothelial cells (HUVECs), EGM media, and
trypsin neutralizing solution from Cambrex; OPTIMEM I (Gibco), bovine serum albumin (BSA;
Santa Cruz), ate buffered saline (PBS; Gibco), Growth Factors including Angiopoietin 1
(Ang1), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) (R&D
s), Tie2 monoclonal antibody (Duke University/P&GP), VEGF receptor 2 (VEGFR2)
polyclonal antibody (Whitaker et. al), protein A/G agarose (Santa Cruz), Tris-Glycine pre-cast
gel electrophoresis/transfer system (6-8%) (Invitrogen), PVDF membranes (Invitrogen), lysis
buffer (20 mm Tris-HCl, 137 mm NaCl, 10% glycerol, 1% triton-X-100, 2 mM EDTA, 1 mM
NaOH, 1 mM NaF, 1 mM PMSF, 1 ug/ml tin, 1 ug/ml pepstatin).
Method: HUVECs are pre-treated for 30 min with antibody (in OPTIMEM) or
M I alone. After removal of pre-treatment, cells are treated with Ang1 (100 ng/ml) for 6
minutes in PBS+0.2% BSA and lysed in lysis buffer. Lysates are run directly on a Tris-Glycine
gel or immunoprecipitated with 2-5 ug/ml Tie-2 antibody or 10 ug/ml R15E6 antibody and
protein A/G agarose. Immunoprecipitated samples are rinsed once with lysis buffer and boiled
for 5 min in 1 X times sample . Samples are ed on a Tris-Glycine gel, erred to a
PVDF membrane, and detected by western blot using the indicated antibodies (pTYR Ab (PY99,
Santa Cruz), Tie-2, VEGFR2 and/or R15E6).
Results: By IP/western blotting, R15E6 recognizes a major, high molecular weight
band tent with the size of HPTPB (Figure 1, Panel A, Lane 2). The less intense, lower
lar weight bands likely represent less glycosylated sor forms of HPTPB. An
immunoprecipitation (IP) with control, non-immune IgG shows no bands in the molecular weight
range of HPTPB (Fig. 1, Panel A, Lane 1), and a combined Tie2/VEGFR2 IP shows bands of the
expected lar weight (Fig. 1, Panel A, Lane 3). This result demonstrates that R15E6
recognizes and is specific for HPTPB.
B. R15E6 Binds Endogenous HPTPB as Demonstrated by FACS Analysis
0] Materials: HUVECs, EGM media, and trypsin neutralizing solution from Cambrex;
Secondary Alexfluor 488-tagged antibody from Molecular Probes; Hanks balanced salt solution
(Gibco); FACSCAN flow cytometer and est software from Becton Dickenson.
Method: HUVECs are trypsinized, treated with trypsin neutralizing solution and
rinsed with HBSS. R15E6 antibody (0.6 ug) is added to 250,000 cells in 50ul of HBSS and
incubated on ice for 20 minutes. Cells are rinsed with 1 ml HBSS followed by adding 2 ug of
fluorescent-conjugated secondary antibody for 20 minutes on ice. Cells are rinsed and
resuspended in 1 ml HBSS then analyzed on the FACSCAN flow cytometer with CellQuest
software. Control cells are d with cent-conjugated secondary antibody only.
Results: By FACS analysis, intact HUVECs, R15E6 causes a robust shift (>90% of
cells) in the fluorescence signal compared to the secondary antibody alone (Fig. 1, Panel B).
This result indicates that R15E6 binds to endogenous HPTPB presented on the surface of intact
elial cells.
EXAMPLE 4
R15E6 Enhances Tie2 Activation
R15E6 enhances Tie2 orylation in the absence and presence of the
oietin 1 (Angl), the Tie2 ligand.
Methods: HUVECs are cultured in serum free media as described above in the
presence or absence of various concentrations of R15E6 and with or without added Angl.
Lysates are prepared, immunoprecipitated with a Tie2 antibody, resolved by polyacrylamide gel
ophoresis and transferred to a PVDF membrane. Membrane-bound precipitated
proteins are then serially western blotted with an antiphosphotyrosine antibody to quantify Tie2
phosphorylation followed by a Tie2 antibody to quantify total Tie2. Tie2 phosphorylation is
expressed as the ratio of the antiphosphotyrosine signal over the total Tie2 signal.
Results: R15E6 enhances Tie2 phosphorylation both in the absence and presence of
Angl (Fig. 2). This result indicates that binding of R15E6 to HPTPB on the surface of endothelial
cells modulates its biological function resulting in enhanced activation of Tie2 in the absence or
presence of .
EXAMPLE 5
Generation of E-PTP extracellular domain antibodies
A. Production of mouse VE-PTP ellular domain protein (VE-PTP-ECD)
VE-PTP —ECD may be ed by any suitable method. Such methods are well
known in the art. For example, VE-PTP —ECD can be produced using a method similar to
Example 1 of the t disclosure where VE-PTP-ECD cDNA is used in place of cDNA
encoding ΗΡΤΡβ-ECD. SEQ ID NO:5 provides a nucleotide sequence that encodes -
ECD. SEQ ID NO:7 provides the amino acid sequence of VE-PTP-ECD.
B. Generation of antibodies to VE-PTP ECD
Anti-VE-PTP antibodies are readily generated by s that are well known
in the art. For example, anti VE-PTP antibodies can be generated using the method of
Example 2 of the present disclosure by tuting VE-PTP-ECD for the ΗΡΤΡβ
extracellular domain and immunizing rats with the resulting protein. The rat anti-mouse VEPTP
antibody used in the present studies was kindly ed by Dr. D. ber (mAb
109). The antibody was generated as described in Baumer S. et al., Blood, 2006, Vol. 107,
pp. 762. y, the antibody was generated by immunizing rats with a VE-PTP-Fc
fusion protein. Immunization, hybridoma-fusion, and screening were conducted as described
in Gotsch U., et al., J Cell Sci., 1997, Vol. 110, pp. 583-588 and Bosse R. and Vestweber D.,
Eur J Immunol., 1994, Vol. 24, pp. 3019-3024.
The fusion protein was constructed such that the first 8 fibronectin type III-
like repeats ending with the amino acid proline at position 732 of VE-PTP were fused in
frame with the Fc part of human IgGl (starting with amino acid proline at position 239). This
construct cloned into pcDNA3 (Invitrogen) was stably transfected into CHO cells, and the
fusion protein was purified by protein A ose affinity purification.
EXAMPLE 6
Intravitreal injections of an anti- VE-PTP ECD antibody
Laser-induced Choroidal Neovascularization Model: The choroidal
neovascularization model is considered to represent a model of neovascular age-related
macular degeneration. Choroidal NV was generated as previously described. See Tobe T, et
al., Am. J. Pathol., 1998, Vol. 153, pp. 646. Adult C57BL/6 mice had laser-induced
rupture of Bruch's membrane in three locations in each eye and were then given 1 µL
itreal injections of 1 or 2 μg of a rat anti-mouse VE-PTP-ECD antibody (IgG2a), in one
eye and vehicle (5% dextrose) in the fellow eye. These treatments were repeated on day 7.
Fourteen days after laser, the mice were perfused with fluorescein-labeled dextran (2xl06
average MW, Sigma, St. Louis, MO) and the extent of neovascularization was assessed in
choroidal flat mounts by fluorescence
microscopy. The area of CNV at each Bruch’s membrane rupture site was measured by image
analysis by an observer masked with respect to treatment group. The area of CNV is the average
of the three rupture sites in one eye. As shown in Fig. 3, treatment with the VE-PTP-ECD
antibody significantly reduced choroidal neovascularization at both 1 and 2 Mg doses versus
treatment with e control.
Example 7
Oxygen-Induced Ischemic Retinopathy
The oxygen-induced ischemic retinopathy model is ered to represent a model of
proliferative diabetic retinopathy. Ischemic retinopathy was ed in C57BL/6 mice by a
method described by Smith, L.E.H., et al. Oxygen-induced retinopathy in the mouse. Invest.
Ophthalmol. Vis. Sci. 35, 101-111 (1994).
C57BL/6 mice at postnatal day 7 (P7) and their mothers were placed in an airtight
chamber and exposed to hyperoxia (75 i 3% oxygen) for five days. Oxygen was continuously
monitored with a PROOX model 110 oxygen ller g Bioinstruments Co., Redfield,
NY). On P12, mice were returned to room air and under a ting microscope, a Harvard
Pump Microinj ection System and pulled glass pipettes were used to deliver a 1 ul intravitreal
injection of 1 or 2 ug of a VE-PTP-ECD antibody was made in one eye and vehicle was injected
in the fellow eye. At P17, the area of NV on the surface of the retina was measured at P17 as
previously described. See Shen J, et al., Invest. Ophthalmol. Vis. Sci., 2007, Vol. 48, pp. 4335-
4341. Briefly, mice were given an intraocular injection of 1 ul containing 0.5 ug rat anti-mouse
PECAM antibody (Pharmingen, San Jose, CA). Twelve hours later, the mice were euthanized,
the eyes fixed in 10% formalin. The retinas were ted, incubated for 40 minutes in 1:500
goat anti-rat IgG conjugated with Alexa488 (Invitrogen, Carlsbad, CA), , and whole
d. An observer masked with respect to treatment group examined the slides with a Nikon
Fluorescence microscope and measured the area of NV per retina by computerized image
analysis using ImagePro Plus software (Media Cybernetics, Silver Spring, MD). Fig. 4 shows
that treatment with the VE-PTP-ECD antibody significantly reduced retinal cularization at
both 1 and 2 Mg doses versus treatment with e l. Fig. 5 shows representative retinal
whole mounts from a mouse treated with vehicle versus a mouse treated with 2 ug of the VE-
PTP-ECD antibody.
2012/060273
Example 8
Subcutaneous injection of a VE-PTP-ECD dy
The oxygen-induced ischemic retinopathy model was conducted as described in
Example 7 inment in a 75% oxygen atmosphere from P5 to P12) for intravitreal dosing
except that the VE-PTP-ECD antibody (1 mg/kg) was dosed subcutaneously at P12 when the
mice were returned to room air and again on days P14 and P16 (three total .
Neovascularization was assessed as described above on day (P17). Fig. 6 shows that
subcutaneous dosing of the VE-PTP-ECD dy s the area of retinal
neovascularization.
Example 9
The experiment described in Example 8 was repeated at a subcutaneous dose of
2 mg/kg. (Fig. 7)
While a number of embodiments of this disclosure are described, it is apparent that
the basic examples may be altered to provide other embodiments that utilize or encompass the
HPTPB-ECD binding agent, methods and processes of this invention. The embodiments and
examples are for illustrative purposes and are not to be interpreted as limiting the disclosure, but
rather, the appended claims define the scope of this invention.
Claims (30)
1. Use of an ΗΡΤΡβ-ECD binding agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the alleviation of vascular leak syndrome in a subject in need thereof.
2. The use of claim 1, wherein the medicament further comprises a pharmaceutically acceptable excipient.
3. The use according to claim 1 or claim 2, wherein the subject is suffering from an inflammatory disease or condition, trauma, shock, adult respiratory distress syndrome, acute lung injury, or sepsis.
4. The use ing to claim 1 or claim 2, wherein the subject is suffering from an inflammatory disease or condition.
5. The use according to claim 1 or claim 2, wherein the subject is undergoing a dosage regime for a cancer.
6. The use ing to claim 5, wherein the cancer is renal cell carcinoma, malignant ma, medulloblastoma, ependymoma, oligodendroglioma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, or glioblastoma.
7. The use according to any one of claims 1 to 6, wherein the ΗΡΤΡβ-ECD binding agent is ated for stration to the subject prior to or during a dosage regime with IL-2.
8. The use according to claim 1 or claim 2, wherein the ΗΡΤΡβ-ECD binding agent is formulated for administration to the subject prior to or during a dosage regime for a cancer.
9. The use ing to claim 8, wherein the cancer is renal cell carcinoma, malignant melanoma, medulloblastoma, ependymoma, endroglioma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, or glioblastoma.
10. The use according to claim 1 or claim 2, wherein the subject is infected with a pathogen.
11. The use according to claim 10, wherein the pathogen is a bacterium, a virus, a yeast, a fungus, or a protozoa.
12. The use according to any one of claims 1 to 11, wherein the ment further comprises an effective amount of an antibacterial agent, an antiviral agent, an anti-fungal agent, or a combination f.
13. The use according to any one of claims 1 to 12, wherein the ΗΡΤΡβ-ECD g agent is an antibody, a protein, a peptide, an aptamer, a peptibody, an adnectin, or a nucleic acid, that binds to an extracellular portion of ΗΡΤΡβ.
14. The use according to any one of claims 1 to 12, wherein the ΗΡΤΡβ-ECD binding agent is a monoclonal antibody, a polyclonal antibody, or an antigen binding nt thereof.
15. The use according to claim 14, wherein the ΗΡΤΡβ-ECD binding agent is a monoclonal antibody.
16. The use according to claim 15, wherein the monoclonal antibody is ed by hybridoma cell line ATCC No. PTA-7580.
17. The use according to claim 13, wherein the ΗΡΤΡβ-ECD binding agent is an antibody, n the antibody has the same or substantially the same biological teristics as the monoclonal antibody produced by hybridoma cell line ATCC No. PTA- 7580.
18. The use according to claim 14, wherein the ΗΡΤΡβ-ECD binding agent is an antigen binding fragment wherein the antigen g fragment is a: F(ab')2, Fab, dimer of an Fab, Fv, dimer of an Fv, or dimer of a scFv.
19. The use according to claim 14, wherein the ΗΡΤΡβ-ECD binding agent is an antigen binding fragment n the antigen binding nt is an F(ab')2, dimer of an Fab, dimer of an Fv, or dimer of a scFv.
20. The use according to claim 14, wherein the antigen binding fragment is an Fab, Fv, or a scFv.
21. The use according to claim 13, wherein the ΗΡΤΡβ-ECD binding agent is a protein, a peptide, an aptamer, a peptibody, an adnectin, or a nucleic acid.
22. The use according to any one of claims 1 to 21, wherein the medicament is formulated with a dose from about 0.01 mg/kg to about 500 mg/kg by weight of the subject.
23. The use according to any one of claims 1 to 21, n the medicament is formulated with a dose from about 0.1 mg/kg to about 10 mg/kg by weight of the subject.
24. The use according to claim 22 or claim 23, wherein the medicament is formulated for administration once daily, three-times weekly, twice weekly, once weekly, three times monthly, twice monthly, once monthly, or once every other month.
25. The use ing to any one of claims 1 to 24, wherein the ECD binding agent is conjugated to a vehicle.
26. The use according to claim 25, wherein the vehicle is PEG.
27. The use according to any one of claims 1 to 26, n the medicament is formulated for administration by intraocular injection.
28. The use according to any one of claims 1 to 26, wherein the medicament is formulated for administration by subcutaneous injection.
29. The use according to any one of claims 1 to 26, wherein the ment is formulated for administration by intravenous injection.
30. The use according to any one of claims 1 to 15, 17, and 22 to 29, n the HPTPβ- ECD binding agent is a humanized antibody. ement Sheet :11: <3.) i...) S... L3... in!“ (swam £352 E N :13 {rm $2: . at. a C)... SUBSTITUTE SHEET (RULE 26) Replacement Sheet E A QEEEE 23583 UMEI 2 nglml
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161546748P | 2011-10-13 | 2011-10-13 | |
US201161546697P | 2011-10-13 | 2011-10-13 | |
US61/546,697 | 2011-10-13 | ||
US61/546,748 | 2011-10-13 | ||
PCT/US2012/060273 WO2013056240A1 (en) | 2011-10-13 | 2012-10-15 | Methods for treating vascular leak syndrome and cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ623283A NZ623283A (en) | 2016-05-27 |
NZ623283B2 true NZ623283B2 (en) | 2016-08-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210095017A1 (en) | Methods for treating vascular leak syndrome and cancer | |
US10618975B2 (en) | Antibody to Renalase | |
BR112021000353A2 (en) | isoform-selective, high-affinity tgfb1 inhibitors and their uses | |
JP2022515188A (en) | Compositions and Methods for Cancer Treatment | |
US20230001006A1 (en) | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers | |
NZ623283B2 (en) | Methods for treating vascular leak syndrome and cancer | |
US20210355235A1 (en) | Compositions and Methods For Treating Cancer with Anti-Renalase antibodies and Anti-PD1 antibodies | |
US20220348684A1 (en) | Anti-Renalase Antibodies for the Treatment and Prevention of Diseases and Disorders | |
JP2022546387A (en) | Intercellular adhesion molecule 1 (ICAM1) antibody drug conjugates and their uses |